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Abstract

DIFFERENTIAL REGULATION OF MLC20 PHOSPHORYLATION IN TONIC AND
PHASIC SMOOTH MUSCLES OF THE STOMACH
By Othman A. Al-Shboul, Ph.D.
A thesis submitted in partial fulfillment of the requirements for the degree of Doctor of
Philosophy at Virginia Commonwealth University.

Virginia Commonwealth University, 2011
Major Director: S.Murthy Karnam
Professor, Department of Physiology

Gastrointestinal (GI) smooth muscle possesses distinct regional and functional properties
that distinguish it from other types of visceral and vascular smooth muscle. On the basis of
electrical properties and contractile phenotype, GI smooth muscles have been classified into
phasic (non-sphinteric) and tonic (sphinteric) smooth muscles. The biochemical basis of phasic
and tonic phenotypes of smooth muscle is not clear and is the major question of inquiry of the
present study. Phosphorylation of Ser19 on the 20 kDa myosin light chain (MLC) is essential for
acto-myosin interaction and contraction in both phasic and tonic muscles. The levels of MLC20

xvi

phosphorylation are regulated by Ca2+/calmodulin-dependent MLC kinase (MLCK) and MLC
phosphatase (MLCP), and the activity of these enzymes are in turn regulated by various signaling
molecules whose expression and activity are important in determining the strength and duration
of their activity. The signaling proteins are AMP kinase (MLCK activity), Rho kinase, zipperinteracting protein kinase (ZIPK), CPI-17 and telokin (MLCP activity), phosphodiesterase 5
(PDE5) and multi-drug resistance protein 5 (MRP5). The overarching goal of the dissertation is
to identify the differences in the signaling pathways that regulate MLCK and MLCP activities,
and thus MLC20 phosphorylation and muscle function.

Using biochemical, molecular and

functional approaches, and antrum (distal stomach) and fundus (proximal stomach) of rabbit
stomach as models of phasic and tonic smooth muscles, respectively, the present study
characterized important differences in the signaling pathways that highly correlate with the
contractile phenotype. These include: 1) tissue-specific expression of contractile proteins such as
myosin heavy chain isoforms, actin, caldesmon, calponin, - and β-tropomyosin, smoothelin-A
and -B; 2) higher expression of AMPK, selective feedback inhibition of MLCK activity via
AMPK-mediated phosphorylation, and higher expression of telokin and activation of MLCP
correlate with the rapid cyclical contractile function in phasic muscle; 3) higher expression and
activation of Rho kinase/ZIPK/MYPT1 and PKC/CPI-17 pathways, preferential inhibition of
MLCP activity, and sustained phosphorylation of MLC20 correlate with the sustained contraction
in tonic muscle; and 4) rapid termination of cGMP signal and muscle relaxation by preferential
degradation and efflux of cGMP via higher expression of PDE5 and MRP5, respectively,
correlate with the brief relaxation and rapid restoration of contraction in tonic muscle. It is
anticipated that these findings could be important in providing the underlying mechanisms
involved in the pathophysiology of smooth muscle function and new insights for the development
of therapeutic agents that should act on smooth muscle in the gut to treat motility disorders as
xvii

well as in other regions such as airways and vascular smooth muscle where similar intracellular
mechanisms may prevail.
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CHAPTER 1
INTRODUCTION AND BACKGROUND

1.1

Introduction
The gastrointestinal (GI) tract is a complex multi-organ system with tissues that differ

structurally and functionally. The dynamic interactions between the neuronal, muscular, immune,
and glandular tissues allow the GI tract to perform its main physiological functions, which
include digestion, absorption, excretion, and protection. Normal gut motility provides for the
mixing and propulsion of intraluminal contents to enable efficient digestion of food, progressive
absorption of nutrients, and evacuation of residues. These fine and delicate GI tract movements
are generated by a highly-regulated interaction between an intricate network of neurons located
within the wall of the alimentary canal (i.e., the enteric nervous system), an intrinsic pacemaker
system (i.e., interstitial cells of Cajal or ICC) and the final effector cells (i.e., smooth muscle
cells).
1.2

GI tract wall
GI tract wall is composed of four layers that have morphological and functional

differences. The four layers, from inside of the gut tube to outside, are the mucosa, the
submucosa, the muscularis propia and the serosa. The smooth muscle of muscularis propia of the
gut consists of a thin, outer longitudinal layer and a thick, densely innervated circular layer (and
another oblique layer in the stomach); the layers derive their names from the orientation of the
1

long axis of muscle cells in them. The muscle cells are separated by laminar septa into bundles
that are embedded in a connective tissue matrix. The muscle layers are separated by neurons,
glial cells, fibroblasts, and interstitial cells of Cajal (ICC)1.
1.3

GI tract smooth muscle
GI tract smooth muscle possesses distinct regional and functional properties that

distinguish it from other types of visceral and vascular smooth muscle. Gut smooth muscles
contract spontaneously in the absence of neural, humoral, or hormonal stimuli and in response to
stretch. They contract as a syncytium (i.e., contract in unison) and therefore classified as unitarytype smooth muscle2.
In general, smooth muscle cells are spindle-shaped of about 400µm in length and 5 to 15
µm wide. They lack the visible cross-striations seen in other muscle types.

Their plasma

membranes consist of two specialized structures known as caveolae and dense bands. The
caveolae are clusters of basket-shaped invaginations of the membrane, the bases of which are
surrounded by the endoplasmic reticulum (called sarcoplasmic reticulum in smooth muscle).
Different caveolin proteins bind to a variety of signaling molecules and act as scaffolds to
facilitate signaling. Clusters of caveolae are separated from each other by electron-dense
structures called dense bands; the site of attachment of thin actin filaments to transmembrane
integrins2.
Two types of coupling connect neighboring smooth muscle cells; mechanical coupling
which is provided by the intermediate junctions - formed by the juxtaposed dense bands from
adjacent cells, and electrical coupling which is provided by gap junctions (or nexuses). Gap
junctions are patches of the closely opposed plasma membranes of adjacent cells, the space of
which is bridged by intercellular channels though which intracellular regulatory molecules like
Ca2+ and cyclic nucleotides are capable of movement between neighboring cells2.
2

Dense bodies are Z-lines-like structures, from which actin thin filaments emerge and
interdigitate with myosin thick filaments. Most of the interior space of muscle cell is occupied by
the contractile filaments and dense bodies while the remainder is occupied by the various
organelles2.

Sarcoplasmic reticulum is located immediately beneath and parallel to plasma

membrane, and is the site of Ca2+ uptake and release3.
1.4

Contractile apparatus; thin and thick filaments
Three types of filaments can be distinguished in smooth muscle cells: thin actin filaments,

thick myosin filaments, and intermediate desmin filaments. Intermediate filaments link dense
bands in the plasma membrane to dense bodies in the cytoplasm4.
Thin filaments consist of actin; a ubiquitous 42 kDa globular protein (G-actin) that
polymerizes to form 2-stranded helical filaments (F-actin). Inserted in the grooves of the actin
helix is another protein, tropomyosin. Thin filaments in smooth muscle have a distinct polarity,
they insert into and emerge from the dense bodies, and they are arranged in bundles that run
parallel to the long axis of the cells, with their free ends surrounding and interdigitating with
thick myosin filaments. Actin filaments are organized through attachments to the dense bodies
that contain α-actinin, a Z-band protein in skeletal muscle4.
Thick filaments are aggregates of myosin molecules formed from the association of six
different proteins: one pair of myosin heavy chains (MHCs) and two pairs of myosin light chains
(MLCs). Myosin II is the molecular motor of muscle cells and the velocity of muscle contraction
is determined by the ATPase activity of myosin as it interacts with actin5. The heavy chains are
coiled around each other to form an α-helical core or tail. Each strand of the core terminates in a
globular head surrounded by two MLCs: a 20 kDa regulatory and phosphorylatable chain
(MLC20) and a 17 kDa chain. Each globular head contains a binding site for actin and an actinactivated magnesium-adenosine triphosphatase (Mg2+-ATP).
3

Hydrolysis of ATP is the fundamental reaction whereby chemical energy is converted into
mechanical energy in smooth muscle. The reaction generates force or induces shortening as a
result of the sliding of the overlapping and interdigitating thin and thick filaments. The force
generated by crossbridge cycling depends on the number of crossbridges acting in parallel. The
crossbridges do not cycle in unison; thus, in smooth muscle, unlike in striated muscle, both the
number and the cycling rate of crossbridges are under regulation6.
1.5

The actomyosin crossbridge cycle
ATP, bound weakly to myosin, is hydrolyzed to ADP and inorganic phosphate (Pi). The

products of hydrolysis remain bound to the myosin head, and the energy released is stored in the
myosin molecule, which has a high affinity for actin in this state. The binding of myosin to actin
can promote a major change in conformation (the power stroke), consisting of a reorientation of
part of the myosin head distal to the actin-binding site which is accompanied by the dissociation
of Pi. Upon release of ADP and Pi, ATP binds again to myosin, which then reverts to a state of
low affinity for actin. Cross-bridge cycling ceases after the stimulus is withdrawn; the
dephosphorylated myosin cross-bridges are arrested in a detached state, which is characteristic of
relaxed muscle7.
A unique pattern of crossbridge cycling is observed during sustained (tonic) contraction
of smooth muscle, in which muscle contraction attains a peak and maintains it near steady state.
This state has been called the “latch” state which represents a transition from a state of rapidly
cycling crossbridges to a state of attached non-cycling or slowly cycling crossbridges. These
latch bridges maintain force in sustained contraction7.
1.6

Neural regulation of smooth muscle contraction
The intrinsic electrical and mechanical properties of smooth muscle are modulated by

neurotransmitters released from neurons of the enteric nervous system, especially neurons of the
4

myenteric plexus. Myenteric plexus contains two main types of neurons: one type contains
inhibitory neurotransmitters such as VIP or PACAP together with NO synthase (NOS), the
enzyme responsible for synthesis of nitric oxide in the nerve terminals, while the majority of the
neurons contain excitatory neurotransmitters, mainly acetylcholine, usually together with
tachykinins; substance P and neurokinin A (NKA), which are released at higher frequencies of
stimulation8.
Excitatory neurotransmitters stimulate Ca2+ release, increase muscle tone, and depolarize
the plasma membrane (i.e., trigger excitatory junctional potentials or EJPs). The depolarization
can result from either a direct action of neurotransmitters on muscle cells or may be mediated
through intramuscular ICC (ICC-IM) which are coupled electrically to muscle cells. EJPs can
induce Ca2+ influx and contraction if the depolarization reaches a level at which voltage-gated
Ca2+ channels open; this is likely to occur in tonic smooth muscle as the membrane potential is
close to the Ca2+ threshold or in phasic smooth muscle during the peak of slow wave activity4.
A large variety of receptors and receptor subtypes have been identified as capable of
mediating smooth muscle contraction. These include receptors for peptides (e.g., tachykinins,
endothelin, motilin), amines (histamine, 5- hydroxytryptamine), pyrimidines/purines (UTP and
ATP), and lipids (S1P, LPA)9.
M2 and m3 receptors are the main muscarinic receptor types expressed in smooth muscle.
Acetylcholine (ACh) interaction with m3 receptor couples it to Gαq leading to activation of
phospholipase C (PLC) and hydrolysis of phosphatidyl inositol (PI) into inositol 1, 4, 5trisphosphate (IP3) and DAG. IP3 binds IP3 receptors on SR and stimulates Ca2+ release and thus
smooth muscle contraction. ACh interacts also with m2 receptor -the predominant (80%) receptor
species in smooth muscle- and couples it to Gαi3 leading to inhibition of adenylate cyclase10,11.
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Inhibitory neurotransmitters, on the other hand, inhibit Ca2+ release, decrease muscle tone
(i.e., relax), and hyperpolarize the plasma membrane directly or indirectly via ICC-IM (i.e.,
trigger inhibitory junctional potentials or IJPs). IJPs lower the plateau potential of slow waves
and inhibit Ca2+ influx and phasic contraction4.
VIP or PACAP induce relaxation by interacting with VPAC2 receptors, which possess
equal affinity for VIP and PACAP. These receptors couple to Gs and thereby lead to activation of
adenylate cyclase (AC) which increases cAMP generation and thus PKA activation. Nitric oxide
activates soluble guanylate cyclase (sGC) which increases cGMP formation, and thus leads to
activation of PKG. Both kinases (PKA and PKG) act in conjunction to cause hyperpolarization
and relaxation of smooth muscle cells12.
1.7

Role of ICC in smooth muscle contraction
ICC are mesenchymal cells, interposed between enteric nerves and smooth muscle cells,

with small cell bodies and several elongated processes and are classified based on their location
and distribution13. They express c-kit, the proto-oncogene that encodes the receptor tyrosine
kinase, kit14. Myenteric ICC (ICC-MY) reside between the longitudinal and circular muscle
layers in the myenteric region. These cells are important as pacemakers; they are spontaneously
active and generate slow wave depolarization in different parts of the GI tract15. Another group of
ICC has an intramuscular location (ICC-IM) with individual ICC being distributed in between
smooth muscle cells. Other morphologically similar ICC are located in the deep muscular plexus
of the small intestine (ICC-DMP). ICC-IM and ICC-DMP are found to be interposed between
nerve terminals and smooth muscle cells and closely associated with neuronal processes16. In
addition, slow waves are modified by other substances such as hormones, paracrine substances,
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and inflammatory mediators. It is not clear yet if these substances have sites of action on ICCIM17.
The amplitude of the slow wave and the resultant contractile force are regulated by the
enteric nervous system. An excitatory neural input (i.e., release of acetylcholine or tachykinins)
increases the amplitude and duration of the plateau potential of slow waves, which then increases
Ca2+ entry and enhances force of contraction. Spike potentials can be superimposed on plateau
potential and further augment intracellular Ca2+ level (or [Ca2+]i) and muscle contraction. On the
other hand, an inhibitory neural input (i.e., release of NO, VIP, or PACAP) activates K+ channels
and suppresses inward current conductance in smooth muscle cells, which thereby reduces the
amplitude of slow waves and attenuates contractile force18.
In rhythmic GI tract parts (e.g., antrum part of the stomach), slow waves -generated by
ICC-MY- depolarize smooth muscle cells to induce the opening of voltage-dependent L-type
Ca2+ channels. The electrical activity of slow waves is propagated through networks of ICC and
conducted passively to smooth muscle cells through gap junctions. These low-resistance
connections between ICC and smooth muscle cells facilitate the propagation of electrical events
from one cell to another4.
The regulation of muscle tone (e.g., fundus part of the stomach which is devoid of ICCMY), however, is not mediated by changes in smooth muscle membrane potential or slow wave
generation but by signaling cascades initiated mainly by enteric neurotransmitters acting directly
on smooth muscle receptors or indirectly via ICC-IM4.
1.8

Peristalsis
Peristalsis is a distinctive pattern of smooth muscle contraction that propels foodstuffs

distally through the GI tract. It was first described by Bayliss and Starling as a type of motility
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wholly mediated by the enteric nervous system in which there is contraction above and relaxation
below the segment being stimulated19. It can be evoked by stroking, initiated by the release of
serotonin (5-HT) from mucosal enterochromaffin cells which acts upon 5-HT receptors of enteric
sensory nerve terminals in mucosa causing the release of the sensory neurotransmitter calcitonin
gene-related peptide (CGRP)20. Peristalsis can also be elicited by radial stretch, which activates
the intramuscular nerve terminals of extrinsic sensory neurons which have axonal projections to
myenteric neurons21.
Peristaltic reflex consists of an ascending and descending phases. During the descending
phase, circular muscle relaxes and longitudinal muscle contracts, while during the ascending
phase, circular muscle contracts and longitudinal muscle relaxes. This reciprocal contraction and
relaxation of the two muscle layers maintain the dimensions of the segment. VIP, PACAP, and
NO are released during and responsible for the descending relaxation of circular muscle, while
acetylcholine, substance P, and NKA are released during and responsible for the ascending
contraction of circular muscle22.
1.9

Signaling for smooth muscle contraction
An essential step in smooth muscle contraction is phosphorylation of the 20 kDa

regulatory myosin light chain (MLC20) by a Ca2+/calmodulin-dependent or -independent myosin
light chain kinase (MLCK) which transfers the phosphate group from ATP to either Ser19 or Thr18
hydroxyl groups of MLC20. This phosphorylation activates the actin-activated myosin ATPase
and actin-myosin interaction, which thereby initiates smooth muscle contraction.
An increase in intracellular free Ca2+ concentration induces activation of Ca2+/CaMdependent MLCK and the phophorylation of MLC20 and thus muscle contraction. The decrease in
intracellular level of Ca2+ induces dissociation of the Ca2+-CaM-MLCK complex, resulting in
8

dephosphorylation of the MLC20 by myosin light chain phosphatase (MLCP) and thus smooth
muscle relaxation9,23. Thus, the phosphorylation level of MLC20 is determined by the opposing
activities of MLCK and MLCP and both of these enzymes‟ activities are well-regulated in
smooth muscle.
1.9.1

MLCK regulation
As mentioned previously, smooth muscle tone is regulated by signaling cascades initiated

by enteric neurotransmitters acting directly on smooth muscle receptors. In circular smooth
muscle cells, contractile agonists activate PLC-β1 via Gαq coupled receptors (e.g., muscarinic m3
receptors) by Gαq binding to PLC-β1‟s COOH-terminal tail24. PLC-β1 hydrolyzes PIP2 into
DAG and IP3. An increase in IP3 leads to the binding of IP3 to the high affinity IP3
receptor/Ca2+ channel on the sarcoplasmic reticulum, resulting in the release of Ca2+ into the
cytosol. Of the two IP3 receptor isoforms (IP3R-I and IP3R-III) expressed in smooth muscle
cells, only IP3R-I mediates Ca2+ release25.
In longitudinal smooth muscle cells, Ca2+ mobilization is dependent on a mandatory step
involving Ca2+ influx via voltage-gated Ca2+ channels25. Upon contractile agonist stimulation,
both Gq- and Gi-coupled receptors activate cytoplasmic PLA2 resulting in phosphatidylcholine
hydrolysis into arachidonic acid which induces membrane depolarization and opening of voltagegated Ca2+ channels. The entry of Ca2+ stimulates cyclic ADP ribose formation and induces
synergistic Ca2+- and cyclic ADP ribose-induced Ca2+ release via ryanodine receptors/Ca2+
channels26.
MLCK activity is strictly dependent on [Ca2+]i which, upon agonist stimulation, increases
as a result of Ca2+ influx into the cytosol through voltage-gated channels and/or the release of
Ca2+ from intracellular stores. Resting levels of [Ca2+]i (70-100nM) increases up to 8-fold during
maximum contraction.
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Four Ca2+ ions bind to calmodulin (CaM) cofactor which then binds to and activates
MLCK27. The transient high levels of [Ca2+]i are then extruded from the cell and/or up taken into
the sarcoplasmic Ca2+ stores. This decrease in the intracellular level of Ca2+ induces dissociation
of the Ca2+-CaM-MLCK complex, which thereupon decreases MLCK activity. MLC20
phosphorylation and contraction, however, are maintained by Ca2+-independent MLCKs and
regulated inhibition of MLCP activity in a process called Ca2+ sensitization23.
Moreover, MLCK activity was shown to be regulated by protein kinases that act to
provide negative feedback mechanisms. Stull and coworkers have found that MLCK is
phosphorylated by CaMKII, and this phosphorylation decreases the activity of MLCK by
decreasing the affinity of the enzyme for calmodulin. It was found that [Ca2+]i required for the
half-maximum activation of CaMKII equals 500 nM, whereas that for MLCK activation is only
250 nM, suggesting a role for CaMKII in inactivation of MLCK when smooth muscle is
hyperactivated and [Ca2+]i rises above some critical level28. A similar mechanism has been
proposed recently with AMP kinase (AMPK) in which AMPK phosphorylates MLCK at Ser815
leading to decreased activity of MLCK. It was found that ablation of AMPK augmented
contraction, suggesting rapid MLCK attenuation and suppression of contraction by AMPK29. In
addition, p21-activated protein kinase 1 (PAK1) was shown to attenuate smooth muscle
contraction by phosphorylating and inactivating MLCK30.
1.9.2

MLCP regulation
While MLCK-mediated contraction is strictly dependent on [Ca2+]i, agonist-induced

MLC20 phosphorylation and contraction can be maintained even after [Ca2+]i returns to basal
levels via two ways; MLC20 phosphorylation by Ca2+-independent MLCKs and regulated
inhibition of MLCP.
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An important step in maintaining contraction via MLCP inhibition involves activation of
RhoA via a cascade leading to sequential agonist-mediated activation of Gq/Gα13 and Rho
guanine nucleotide exchange factor (Rho-GEF) 30,31. Activated Rho A (Rho-GTP) is translocated
to the plasma membrane where it activates both Rho kinase -mainly Rho kinase II, the
predominant smooth muscle isoform- and PLD32. Hydrolysis of phosphatidylcholine by PLD
yields phosphatidic acid, which is dephophorylated to diacylglycerol, resulting in sustained
activation of Ca2+-dependent and -independent PKC isozymes. Rho kinase and PKC act
concurrently and cooperatively to inhibit MLCP activity9.
The same receptors that initiate Ca2+ mobilization and MLCK-mediated MLC20
phosphorylation and contraction also engage a distinct G protein-dependent pathway that
mediates Ca2+-independent MLC20 phosphorylation and contraction via negative regulation of
MLCP. Some receptors (e.g., m3 receptors) are coupled to RhoA via G13 only, whereas others
(e.g., SIP2 and motilin receptors) are coupled to RhoA via both Gq and G1330,33,34.
Structurally, MLCP holoenzyme consists of three subunits; a 37 kDa catalytic subunit of
type 1 phosphatase (ppicδ), a 110 to 130 kDa regulatory subunit, known as myosin phosphatase
target subunit I or MYPT1, and a 20 kDa subunit of unknown function. MYPT1 binding to the
catalytic subunit enhances MLCP catalytic activity35.
Phosphorylation of MYPT1 at Thr696 by Rho kinase promotes dissociation of the catalytic
and regulatory subunits of MLCP and inhibits its catalytic activity

36

. Rho kinase also

phophorylates Thr853 within the myosin-binding domain on MYPT1 upon which the enzyme
dissociates from myosin and decreases the efficiency of the enzyme by decreasing availabilty of
the substrate31. On the other hand, phosphorylation of an adjacent Ser695 by cAMP- or cGMPdependent protein kinase (PKA and PKG, respectively) blocks the ability of Rho kinase to
phosphorylate Thr696 and so restores MLCP activity 37.
11

PKC, mainly PKC-ε and PKC-δ, phosphorylates CPI-17, a 17 kDa endogenous inhibitor
of MLCP, at Thr38 and greatly enhancing its ability to inhibit MLCP

38

. Thus, a dual Rho-

dependent mechanism (i.e., via Rho kinase and PKC activation) causes sustained inhibition of
MLCP. The relative involvement of Rho-mediated pathways-Rho kinase/MYPT1 and PKC/CPI17- in MLCP inhibition appears to be receptor-specific. Most Gq/13-coupled receptors (e.g., m3,
S1P2, motilin) engage both pathways. ETA receptors engage only Rho kinase/MYPT1 while
LPA3 receptors engage only PKC/CPI-1733,34,39,40.
Zipper interacting protein kinase (ZIPK) was also found to inhibit MLCP. It is a
serine/threonin kinase expressed in various tissues including smooth muscle and is a member of
the death–associated protein kinase (DAP) family41. ZIPK co-localizes with MLCP and is
phosphorylated following activation of Rho kinase-dependent pathway during carbachol
stimulation of rabbit bladder. The phosphorylated ZIPK, in turn, phosphorylates the myosinbinding subunit at Thr696, considerably faster and even more effective than Rho kinase42,43. Niiro
and Ikebe, however44, have demonstrated that MYPT1 is a poor substrate for ZIPK, and instead,
ZIPK acts as a Ca2+-independent MLCK that directly phosphorylates MLC20 at both Ser19 and
Thr18 in absence of Ca2+. It has been suggested that the myofilament-bound ZIPK may mediate
Rho kinase–dependent phosphorylation of MYPT1 and inhibition of MLCP and thus could be the
link between the activated plasma membrane-bound Rho kinase and MYPT1.
Integrin-linked kinase (ILK) is another myofilament-bound Ca2+-independent MLCK. It
mediates MLC20 phosphorylation, at both Ser19 and Thr18, and smooth muscle contraction
through Gi-coupled receptors. These receptors sequentially activate ILK through certain pathway
involving PI3-kinase activation via Gβγi45.
1.10

Regulation of smooth muscle contractility by thin filament-associated proteins
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The thin filaments are defined as those filaments 6–8 nm in diameter and composed of
filamentous actin. They are different from the intermediate filaments (10 nm), the myosin
filaments (15-18 nm), and the microtubules (~24 nm)46. Some proteins have been suggested to
bind actin and possibly regulate smooth muscle contraction. Thin filament-associated proteins
include: Tropomyosin (Tm), caldesmon (CaD), calponin (CaP), and smoothelin.
1.10.1 Tropomyosin (Tm)
Tm is a coiled-coil α-helix that spans seven actin monomers. Individual molecules
interact head to tail, thereby creating a continuous strand along the actin filament47. Functionally,
X-ray and fluorescent resonance energy transfer studies have shown that activation of smooth
muscle leads to movement and displacement of Tm away from actin monomers, i.e., exposing
myosin-binding sites on actin for myosin binding and thus forming cross-bridges48,49. Moreover,
Tm is necessary for full inhibition of actomyosin ATPase activity by CaD50. Two Tm isoforms
appear to be specific to smooth muscle; α-Tm and β-Tm. PKC-mediated phosphorylation and
displacement of TM is associated with smooth muscle contraction by enhancing the cooperative
activation of actomyosin51.
1.10.2 Calponin (CaP)
Calponin was first found in smooth muscle cells as a striated muscle troponin-like protein
with a proposed function in the regulation of smooth muscle contraction52. Calponin is now wellknown as a family of actin filament-associated proteins of 34-37 kDa expressed in both smooth
muscle and non-muscle cells. Three isoforms of calponin have been found in the vertebrates as
the products of three homologous genes53; a basic calponin (h1-calponin), which is the chicken
gizzard calponin ortholog, a neutral calponin (h2-calponin), and an acidic calponin (h3-calponin).
h1-calponin is specific to differentiated smooth muscle cells and up-regulated during post-natal
development, while both h2 and h3-calponins are expressed in both muscle and non-muscle
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tissues54. There is an in vitro experimental evidence that calponin inhibits actin-activated myosin
ATPase55.
In vitro phosphorylation of CaP (most probably at Ser175 and Thr184) by several kinases
(such as PKC-ε) resulted in the loss of its ability to bind F-actin to inhibit both actomyosin Mg2+ATPase activity56 and unloaded shortening velocity57.
1.10.3 Caldesmon (CaD)
Caldesmon is another actin-binding protein that is present in both smooth muscle and
non-muscle cells. The heavier smooth muscle isoform (h-caldesmon, 87 kDa) is found in
differentiated „contractile‟ smooth muscle cells, whereas the lighter isoform (i-caldesmon, 57
kDa) is expressed in both non-muscle cells and „synthetic‟ smooth muscle cells58. Caldesmon
binds myosin, actin, tropomyosin, and calmodulin and inhibits the actin-activated myosin
ATPase by blocking the interaction of actin and myosin59 and/or inhibiting a kinetic step of the
actomyosin ATPase cycle60. Inhibition of contraction by caldesmon can be released by its
binding

to

Ca2+/calmodulin61

or

via

posttranslational

phosphorylation

at

Ser789

62

.

Immunocytochemical studies of chicken gizzard smooth muscle have revealed that CaD is
colocalized with contractile proteins, while CaP is associated with both contractile and
cytoskeletal proteins63.
1.10.4 Smoothelin
Smoothelins are smooth muscle α actin stress fibers-binding proteins that are specifically
and abundantly expressed in contractile smooth muscle cells, absent or limited in non-contractile
and proliferative smooth muscle cells or cells with smooth muscle-like features, and are the only
marker that differentiates between smooth muscle cells and myofibroblasts64. They are encoded
by a single-copy gene via dual promoter system that generates two major isoforms containing a
troponin T-like domain; A (59 kDa) and B (110 kDa) isoforms65. Lack of smoothelin-A, the main
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isoform in visceral smooth muscle, decreases intestinal contractions in response to both receptormediated (e.g., ACh) and non receptor-mediated contractile agonists (e.g., KCl), but the
mechanism of regulation is yet unknown66.
1.11

Signaling for relaxation
Smooth muscle relaxation is initiated by targeting MLC20 dephosphorylation. This

involves either MLCK inactivation and/or removal of MLCP inhibition. Most agents cause
relaxation by stimulating the production of cAMP (e.g., VIP and its homologue PACAP) or
cGMP (e.g., nitric oxide [NO]) leading to activation of PKA, PKG or both. Cyclic AMPactivated PKA and cGMP-activated PKG are the main enzymes that induce relaxation in smooth
muscle. They target different components of the contractile signaling pathways that attenuate
MLCK activity and/or augment MLCP activity which eventually induce dephosphorylation of
MLC20 and thus smooth muscle relaxation9.
1.11.1 Cyclic nucleotide regulation:
The levels of cAMP and cGMP in gastrointestinal smooth muscle depend on the rates of
their synthesis by cyclases and degradation by phosphodiesterases (PDEs). Cyclic AMP, which is
produced in ~10-fold greater amounts than cGMP, is generated from ATP via the membranebound adenylate cyclase (AC) -type V and VI- and is rapidly degraded by the cAMP-preferring
PDE3 and cAMP-specific PDE4. On the other hand, cGMP is generated from GTP via the
soluble guanylate cyclase (sGC) and is rapidly degraded by cGMP-specific PDE5. PKA inhibits
AC while PKG inhibits sGC. Both PDE3 and PDE4 are activated by PKA, but only PDE3 is
inhibited by cGMP. On the other hand, PDE5 is activated by PKG. When both cAMP and cGMP
are present, PDE5 is also activated by PKA67-69. So, regulatory feedback from the protein kinases
inhibits synthesis and accelerates degradation, and thereby maintains the levels of cyclic
nucleotides within a narrow range.
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Although cAMP preferentially activates PKA, it can, at higher concentrations, also crossreactivate PKG70. An increase in both cAMP and cGMP, such as that brought about by corelease
of NO, VIP, and PACAP from the same or adjacent nerve terminals, is the physiological norm
during nerve-induced relaxation of the gut. Inhibition of PDE3 by cGMP enhances cAMP levels,
whereas activation of PDE5 by PKA and PKG greatly increases its affinity for the more abundant
cAMP. Under these conditions, PKG is activated by both cGMP and cAMP 69,71.
In addition to degradation by phosphodiesterases, cyclic nucleotides elimination pathways
comprise active export into the extracellular space via members of the multidrug resistance
protein (MRP) family (the other name is ABC transporters). MRPs bind and hydrolyze ATP,
providing the energy to transport their substrates across membrane barriers. Among the MRP
family membes, MRP4 and MRP5 have been shown to be competent in the transport of cAMP
and cGMP respectively72.
1.11.2 PKA and PKG targets
PKA and PKG indirectly target MLCK inactivation by primarily decreasing [Ca2+]i. Both
PKA and PKG can inhibit Ca2+ mobilization by inhibiting IP3 formation in circular muscle and
arachidonic acid formation in longitudinal muscle. Inhibition of IP3 formation in circular muscle
involves phosphorylation of RGS4, leading to more rapid degradation of Gαq-GTP and inhibition
of PLC-β1 activity. PKG-mediated phosphorylation of SERCA2 and sarcoplasmic reticulum IP3
receptors accelerates Ca2+ reuptake into the stores and inhibits IP3-induced Ca2+ release,
respectively. In addition, both kinases inhibit the activity of membrane Ca2+ channels and
stimulate the activity of membrane K+ channels, leading to hyperpolarization of the plasma
membrane and interruption of Ca2+ influx into the cell, a mechanism that is important in relaxtion
of rhythmic contraction9.
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Moreover, PKG and PKA augment MLCP activity by different ways; first, they
phosphorylate the activated form of RhoA (Rho-GTP) at Ser188 leading to its inactivation and
translocation back to the cytosol

73

. Second, both enzymes can phosphorylate MYPT1 at Ser695,

preventing the inhibitory regulation of Rho kinase-mediated phosphorylation of MYPT1 at Thr696
37

. Finally, both kinases are able to phosphorylate (at Ser13) and enhance the activity of telokin, a

smooth muscle-specific endogenous activator of MLCP 74.
1.12

Phasic and tonic smooth muscles
Based on the membrane properties, activation speed and contractile behavior, smooth

muscles have been classified as either phasic or tonic23. Phasic muscles, like those in the distal
stomach (or antrum), ileum, and taenia coli, generate action potentials, shorten rapidly, and
typically produce spontaneous and rapid contractions and do not maintain force for extended
periods of time. These muscles exhibit variable tones on which are superimposed rhythmic or
phasic contractions driven by cycles of membrane depolarization and repolarization known as
slow waves, which are believed to be generated by ICC. Tonic smooth muscles, on the other
hand, do not generate action potentials or spontaneous contractions, but are specialized to
contract slowly and maintain contractile force for long durations. Examples of tonic smooth
muscles include proximal stomach (or fundus), sphincters, and gall bladder9.
The phasic and tonic behavior of smooth muscles may also be related to differences in
content and isoform composition of contractile proteins and intracellular signaling molecules that
regulate the activities of myosin light chain kinase (MLCK) and myosin light chain phosphatase
(MLCP). For example, previous studies have shown that phasic muscle differs from the tonic
muscle in the relative abundance of the ratio of acidic to basic isoforms of the 17 kDa essential
light chain and the seven amino acid-inserted to non-inserted myosin heavy chain isoforms
(SMA/SMB isoforms)75,76.
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MLCK activity is stimulated by an increase in Ca2+ via Ca2+/calmodulin complex, and
inhibited by Ca2+/calmodulin-dependent protein kinase II in a feedback mechanism. Moreover,
recent studies have shown that smooth muscle contraction is attenuated by phosphorylation and
inactivation of MLCK via AMP-dependent kinase (AMPK).

MLCP activity is inhibited via

PKC-mediated phosphorylation of the endogenous inhibitor CPI-17, and activated via PKA- and
PKG-dependent phosphorylation of the endogenous activator telokin. PKA and PKG are the two
main kinases responsible for smooth muscle relaxation by targeting different components in the
signaling pathways of MLCK and MLCP. They are activated by an elevation in cAMP and
cGMP respectively, the level of which is dependent on the balance between their generation by
cyclases and degradation by phosphodiesterases.
It is not known, however, whether the expression and regulation of the signaling
molecules that regulate MLCK and MLCP are different in phasic and tonic smooth muscle. The
purpose of our study is to comprehensively compare the content and regulation of the different
signaling molecules that regulate MLCK and MLCP as well as highlighting the differences in the
contractile and thin-filament associated proteins in phasic versus tonic smooth muscle of the
gastrointestinal tract.
1.13

Stomah”proximal vs. distal”
The purpose of this study is to comprehensively compare the content and regulation of

different contractile proteins and signaling pathways that regulate MLCK and MLCP activity in
phasic versus tonic smooth muscle of the gastrointestinal tract as well as highlighting other
aspects of general significance in smooth muscle physiology.

This thesis explores these

differences in the antrum (represents phasic smooth muscles) versus the fundus (represents tonic
smooth muscles) parts of the stomach, and so, I found it valuable to have some physiological
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anatomy and membrane potential characteristics of the stomach and brief description of some
gastric disorders that are related to the improper smooth muscle function in this organ.
The main motor function of the stomach is to serve as an active reservoir that stores and
mixes ingested food as well as modulates its rate of emptying into the duodenum. Stomach is
divided into two major functional areas; the proximal stomach and the distal stomach. The
proximal stomach consists of the fundus and the upper body (or corpus). The primary function of
the proximal stomach is to accommodate ingested food. The distal stomach consists of the lower
body and the antrum. The primary function of distal stomach is to regularly push digested food
into the duodenum in a well-coordinated fashion77.
The membrane potential of gastric smooth muscle exhibits a characteristic gradient
decreasing from −48 mV in the fundus to −71 mV in the antrum78. Unlike the distal stomach, the
proximal stomach membrane potential does not demonstrate phasic changes in potential, in other
words it is electrically quiescent (without slow waves). Consequently, under basal conditions, the
fundus exhibits tone rather than pulsation which, in turn, can be modulated by small changes in
neural and hormonal inputs79. Fundus is suitable for receiving (i.e., vagal-mediated receptive
relaxation) and discharging (i.e., tonic contraction) a meal upon inhibitory (hyperpolarizing) or
stimulatory (depolarizing) inputs respectively.
It is believed that corpus is the site of spontaneous pacemaker activity or slow wave
generation in the stomach80. Slow waves originating in the corpus paropagate to and pace antral
muscle. Unlike the fundus, the distal body of the stomach and the antrum exhibit phasic rather
than tonic motor activity. This is often seen on endoscopy as a powerful ring-shaped peristaltic
wave, which initiates in the mid to distal body of the stomach, picking up strength as it drives
towards the pylorus where it abruptly terminates81. As contractions or electrical activity
corresponding to contractions reach pylorus, the pylorus begins to open or relax.
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The frequency and direction of the phasic motor activity are tightly coupled with the
gastric slow wave generated by phasic depolarization of the interstitial cells of Cajal82. A slow
wave frequency of three cycles per minute is present during both the resting and active phases of
gastric motor activity. Neurohumoral activators increase the slow wave amplitude and this
initiates a coupled peristaltic response that grinds and triturates food into a fine particulate
suspension, ready for passage into the duodenum83.
In a number of disease states or conditions, these peristaltic contractions of the stomach
and/or the opening and closing of the pylorus is irregular. Gastroparesis or delayed gastric
emptying may result in insufficient contractions to churn food, move food through the pylorus,
and/or open the pylorus, resulting in gastro retention of food84. In another motility disorder
known as dumping syndrome, the stomach empties at an abnormally high rate into the small
intestine causing various gastrointestinal disorders84.
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SIGNIFICANCE

Although, the initial classification was based on membrane properties and contractile
behavior, recent studies suggests that these muscle types exhibit differences in several cellular
properties, from membrane activation, cell signaling to the actin-myosin interaction. Previous
studies suggest that the phasic and tonic behavior of smooth muscles may be related to
differences in content and isoform composition of contractile proteins.

Understanding the

differences in the signaling pathways that regulate MLCK and MLCP activities and cGMP levels
using biochemical, molecular and functional approaches, and antrum (distal stomach) and fundus
(proximal stomach) of rabbit stomach as models of phasic and tonic smooth muscle, respectively,
is the major question of inquiry of the present study. An understanding of the mechanisms that
regulate tone and relaxation at the intracellular levels is important in the pathophysiology and
may provide new insights for the development of therapeutic agents that should act on smooth
muscle in the gut to treat motility disorders as well as in other regions such as airways and
vascular smooth muscle where similar intracellular mechanisms may prevail.
To understand the biochemical basis of phasic and tonic contractile phenotype, I have
undertaken a systematic analysis of signaling proteins whose expression and activity are
important in the regulation of MLCK and MLCP activity and cGMP levels. The signaling
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proteins are AMPK (MLCK activity), Rho kinase, ZIP, CPI-17 and telokin (MLCP activity) and
PDE5 and MRP5 (cGMP levels).
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HYPOTHESIS AND SPECIFIC AIMS

The following are the Specific Aims and underlying hypotheses.
Specific Aim 1:

Identification of differences in the signaling pathways mediating

termination of MLCK activity and muscle contraction.
Hypothesis. Expression and function of AMPK-dependent pathway involved in the
termination of Ca2+/CaM-dependent MLCK activity are higher in phasic muscle than tonic
muscle.
Specific Aim 2: Identification of differences in the signaling pathways mediating MLCP
inhibition and sustained muscle contraction.
Hypothesis. Expression and function of Rho kinase/ZIPK/MYPT1 and PKC/CPI-17
pathways involved in the suppression of MLCP activity are higher in tonic muscle than phasic
muscle.
Specific Aim 3:

Identification of differences in the signaling pathways mediating

termination of cGMP signaling and muscle relaxation.
Hypothesis. Expression and function of cGMP degradation (PDE5) and efflux (MRP5)
are higher in tonic muscle than phasic muscle.
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CHAPTER 2
MATERIALS AND METHODS

2.1

Materials
[125I]cGMP, [-32P]ATP, and [32P]Pi were obtained from PerkinElmer Life Sciences,

Boston, MA; Collagenase CLS type II and soybean trypsin inhibitor were obtained from
Worthington, Freehold, NJ; Western blotting, Dowex AG-1 X 8 resin (100-200 mesh in formate
form), chromatography material and protein assay kit, Tris-HCl Ready Gels were obtained from
Bio-Rad Laboratories, Hercules, CA; antibodies to MLCK, AMPK, Rho kinase II, PKC-ε, ZIPK,
telokin, CPI-17, PDE5, MYPT1, phospho-MLC20, α-actin, smoothelin, tropomyosin, caldesmon,
calponin-1, and MRP5 were obtained from Santa Cruz biotechnology, Santa Cruz, CA; myelin
basic protein (MBP) was obtained from Upstate Biotechnology; Y27632, STO609, Phorbol 12myristate 13-acetate (PMA), cGMP, PKI(6-22) amide were obtained from Calbiochem, La Jolla,
CA; RKRSRAE was obtained from Peninsula Laboratories, Belmont, CA; RNAqueousTM kit was
obtained from Ambion, Austin, TX; Effectene Transfection Reagent, QIAEX®II Gel extraction
Kit and QIAprep®Spin Miniprep Kit were obtained from QIAGEN Sciences, Maryland; PCR
reagents were obtained from Applied Biosystems, Roche; SuperScriptTM II Reverse Transcriptese
and TOPO TA Cloning® Kit Dual Promoter were obtained from Invitrogen, CA; Dulbecco‟s
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modified Eagle‟s medium (DMEM) was obtained from Fisher Scientific. All other chemicals
were obtained from Sigma, St. Louis, MO.
New Zealand white rabbits (weight: 4-5 lbs) were purchased from RSI Biotechnology,
Clemmons, NC and killed by injection of euthasol (100 mg/kg), as approved by the Institutional
Animal Care and Use Committee of the Virginia Commonwealth University. The animals were
housed in the animal facility administered by the Division of Animal Resources, Virginia
Commonwealth University. All procedures were conducted in accordance with the Institutional
Animal Care and Use Committee of the Virginia Commonwealth University.
2.2

Methods

2.2.1

Collection of tissue
Rabbits were sacrificed by injection of Euthasol (100 mg/kg body weight) into the ear

vein. The stomach was rapidly removed, emptied of its contents and placed in a cold smooth
muscle buffer with the following composition: NaCl 120 mM, KCl 4 mM, KH2PO4 2.6 mM,
CaCl2 2.0 mM, MgCl2 0.6 mM, HEPES (N-2-hydroxyethylpiperazine-N‟ 2-ethanesulfonic acid)
25 mM, glucose 14 mM, and essential amino mixture 2.1% (pH 7.4)85-87.
2.2.2

Preparation of dispersed gastric smooth muscle cells
Smooth muscle cells from the circular muscle layer of the antrum and fundus were

isolated by sequential enzymatic digestion of muscle strips, filtration, and centrifugation as
described previously

32,85-87

. The tissue was cut into thin slices using a Stadie-Riggs tissue slicer

and then the slices were incubated for 30 min in a smooth muscle buffer at 31C containing 0.1%
collagenase (300 U/ml) and 0.01% soybean trypsin inhibitor (w/v). The tissue was continuously
gassed with 100% oxygen during the entire isolation procedure. The partly digested tissues were
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washed twice with 50-ml of collagenase-free smooth muscle buffer and the muscle cells were
allowed to disperse spontaneously for 30 min in collagenase-free medium. Cells were harvested
by filtration through 500 μm Nitex and centrifuged twice at 350 g for 10 min to eliminate broken
cells and organelles. The cells were counted in a hemocytometer and it is estimated that 95% of
the cells excluded trypan blue. The experiments were done within 2-3 h of cell dispersion.
2.2.3

Permeabilization of smooth muscle cells
Dispersed muscle cells were permeabilized by incubation for 10 min with 35 µg/ml of

saponin in a medium containing 20 mM NaCl, 100 mM KCl, 5 mM MgSO4, 1 mM NH2PO4, 25
mM NaHCO3, 0.34 mM CaCl2 and 1 mM EGTA with 1% bovine serum albumin25. The cells
were centrifuged at 350 g for 5 min, washed free of saponin, and resuspended in the same medium
with 1.5 mM ATP and ATP-regenerating system (5 mM creatine phosphate and 10 U/ml creatine
phosphokinase).
2.2.4

Preparation of cultured gastric smooth muscle cells
Dispersed muscle cells isolated from the antrum and fundus were resuspended in DMEM

containing penicillin (200 U/ml), streptomycin (200 g/ml), gentamycin (100 g/ml),
amphotericin B (2.5 g/ml) and 10% fetal bovine serum (DMEM-10). The muscle cells were
plated at a concentration of 5 X 105 cells/ml and incubated at 37C in a CO2 incubator. DMEM10 medium was replaced every three days for 2-3 weeks until confluence was attained. The
muscle cells in confluent primary cultures were trypsinized (0.5 mg trypsin/ml), re-plated at a
concentration of 2.5 X 105 cells/ml and cultured under the same conditions. All experiments were
done on cells in the first passage. Previous studies have determined the purity of cultured muscle
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cells with smooth muscle-specific -actin88. Cultured muscle cells were starved in serum-free
medium for 24 hours before each use.
2.2.5 Expression of MRP5, α-actin, β-actin, γ-actin, and myosin isoforms (SM1, SM2, SMA,
SMB) by RT-PCR
Total RNA was isolated from freshly dispersed smooth muscle cells with TRIzol® reagent
(Invitrogen) and cultured gastric muscle cells using ULTRASPECTTM reagent from both antrum
and fundus regions of the stomach and then treated with TURBO DNase (Ambion) . RNA from
each preparation was reversely transcribed using the SuperScript™ II system containing 50 mM
Tris–HCl (pH 8.3), 75 mM KCl, 3 mM MgCl2, 10 mM dithiothreitol (DTT), 0.5 mM
deoxynucleoside triphosphates (dNTP), 2.5 μM random hexamers and 200 units of reverse
transcriptase in a 20 μl reaction volume. The reactions were carried out at room temperature for
10 min and at 42°C for 50 min, and terminated by heating at 70°C for 15 min. Three μl of the
reversely transcribed cDNA was amplified in a final volume of 50 μl by PCR in standard
conditions (2 mM MgCl2, 200 μM dNTP, 2.5 units Taq polymerase) with specific primers
designed based on conserved sequences in human, rat and mouse cDNAs (Table 1). PCR was
performed for 30 cycles. For each experiment, a parallel control without reverse transcriptase was
processed. The amplified PCR products were analyzed on 1.5% agarose gel containing 0.1 μg/ml
ethidium bromide.
2.2.6 Expression of telokin, CPI-17, α-tropomyosin, β-tropomyosin h-caldesmon, h1calponin, and smoothelin-A and smoothelin-B by Real Time PCR
Real-time PCR was performed on cDNA samples synthesized from total RNA isolated
from freshly dispersed smooth muscle cells and whole gastric tissue from antrum and fundus with
TRIzol® reagent (Invitrogen) and from antrum and fundus cultured gastric muscle cells with the
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StepOne™ Real-Time PCR System (Applied Biosystem, Foster city, CA) and the intercalating
dye, SYBRgreen. Methods for total RNA isolation and cDNA synthesis were followed for the
real-time PCR experiments. PCR conditions were optimized on the gradient thermal cycler on the
StepOne™ Real-Time PCR System. For each cDNA sample, real-time PCR was conducted in a
20 μl reaction volume containing Quantitect

TM

SYBRgreen PCR Mastermix (Qiagen,

Mississauga, ON). The following time and temperature profile was used for the real-time PCR
reactions: 95 ˚C for 5 min; 50 cycles of a series consisting of 15 s at 94 ˚C, 30 s at 52 ˚C, 30 s at
72 ˚C; and a final extension of 5 min at 72 ˚C. The optimal annealing temperatures were
determined empirically for each primer set. The sequences of specific primers are listed in Table
1.
Real-time PCR reactions were performed in triplicate. Each primer set generated only one
PCR product, and the identity and integrity of these products were confirmed by electrophoresis
on 1.5% agarose gel containing 0.1 μg/ml ethidium bromide and sequencing of the individual
bands. The fluorescent threshold value was calculated using the StepOne™ Real-Time PCR
System software. The absence of peaks in water controls suggested a lack of primer-dimer
formation.
Quantification of gene expression. Two general types of quantification strategies can be
performed in quantitative RT-PCR (qRT-PCR). The levels of expressed genes may be measured
by an absolute quantification or by a relative qRT-PCR. The absolute quantification approach
relates the PCR signal to input copy number using a calibration curve89.
Relative quantification relates the PCR signal of the target transcript in a treatment group
to that of another sample such as an untreated control. Relative quantification of a target gene in
relation to another gene (reference gene or housekeeping gene) can be calculated on the basis of
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delta delta CT values (CT, called as well CP, is the cycle number at which the fluorescence
generated within a reaction crosses the threshold. CT reflects the point during the reaction at
which a sufficient number of amplicons has accumulated). There are several mathematical
models to calculate the relative expression ratio (R), based on the comparison of the diverse cycle
differences. Among them are the delta delta CT method 90 and the efficiency corrected calculation
model91. In these models, the target-gene expression is normalized to the expression of one or
more non-regulated housekeeping genes. The choice of an internal control to normalize the
expression of the gene of interest is critical to the interpretation of experimental real-time PCR
results. The housekeeping gene expression must not be influenced by the applied treatment92.

Delta delta CT method

ΔΔCT = (CT, Tag − CT, HKG) Treatment − (CT, Tag − CT, HKG) Control
−ΔΔCT

R=2
Where, HKG is the housekeeping gene and Tag, the evaluated gene.
Following the criteria for choosing the reference genes and delta delta method, in this study
GAPDH was selected as reference gene. After normalization, the data for antrum were expressed
as the fold-change in mRNA expression relative to that obtained for fundus.
2.2.7 Transfection of dominant negative mutants and minigene constructs into cultured
smooth muscle cells.
Wild type telokin and phosphorylation-deficient telokin (S13A) were subcloned into the
multiple cloning site (EcoR I) of the eukaryotic expression vector pcDNA3. Recombinant plasmid
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Table 1. Real-time and RT-PCR primer sequences. Primers for amplification of different
genes from smooth muscle tissue. AMPK; AMP kinase, MLCK; myosin light chain kinase,
ZIPK; zipper interacting protein kinase, CPI-17; PKC potentiated inhibitor 17 kDa protein,
PDE5; phosphodiesterase 5, MRP5; multi-drug resistance protein 5, Tm; tropomyosin, CaD;
caldesmon, CaP; calponin, GAPDH; Glyceraldehyde 3-phosphate dehydrogenase, SMA/B;
smooth muscle myosin (isoforms A and B), SM1/2; smooth muscle myosin (isoforms 1 and 2).
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Primer set

Forward 5’3’

Reverse 3’5’

Size (bp)

AMPK

TATGGTGGTCCACAGAGATTTGA

TTTGCATTCATGTGTGCATCA

63

MLCK

GCCGAGCAGATGGATTTCC

CTCTCCTCCTCAGACACAGTCTTG

71

CCAAACCTCTCTGGCATGTCTT

TTAACATGGCATCTTCGACATTCT

ATCCGCCACCCCAACAT

TCAGCACCACATCTGTCTTGTTC

Telokin

AACGGGCAATGCTGTGAGA

GCCCTGAGATCATTGCCATAG

69

CPI-17

GAGCAAGCTGCAGTCCCCGT

GATCCACTTCTCCACGTCCA

116

PDE5

CTATTCCCTGTTCCTTGTCTGTGA

CAAAGAGGCGGCTGATAAGAA

65

MRP5

GCAAGAGCCCTGCTGCGTCA

CTGTGTGCAGGCGATGGGCA

151

α-actin

GTCACTTCCCTGCTCTGT

GCTTTGGATAGGCATGACT

β-actin

CCCTCCATCGTGCACCGCAA

CTCGTCTCGTTTCTGCGCCGT

γ –actin

ATCAGGCCCGCGACACTCGT

α-Tm

CTGAAGCCGATGTAGCGTCTCTG

ACGCTCCTGGGCACGATCCA

β-Tm

CCTCCCTGAACCGCCGCATT

TGACAAGACGCTCCTGCGCC

CAGAAGGGAAGTCGGTAAATGAAA

GGGCAGCTGTCTGAAGTTTATCTTCTT

GGTGAAGCCCCACGACAT

CAAAGCCAGGAGGGTGGACTG

Smoothelin-A

GCTGGTAAAAACCAAAAAGTCCTAA

GCTTTTTGCCCATGATCATCA

107

Smoothelin-B

ATGAGGAGCGCAAGCTGATC

GGCAGCCTCAATCTCCTGAGC

65

GAPDH

GCCTGGAGAAAGCTGCTAAGTATG

CCTCGGATGCCTGCTTCA

60

CAGTCCATTCTCTGCACAGG

TCATTCTTGACCGTCTTGGC

TGAAGCAGAGGGACAAGAAG

TTCTGGTAGGAACGAACGAG

Rho Kinase

ZIPK

h-CaD

h1-CaP

SMA/B

SM1/2

GCCGCCAGTGTGCTCTAAAGGT
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64

64

97

100

70

75

67

61

86

197/218

230/291

DNAs were transiently transfected into the muscle in primary culture using Effectene
Transfection Reagent (QIAGEN) for 48 h. Cells were co-transfected with 2 g of pcDNA3
vector and 1 g of pGreen Lantern-1 DNA. Transfection efficiency was monitored by the
expression of the green fluorescent protein using FITC filters. Control cells were transfected with
vector alone. Analysis by fluorescence microscopy showed that approximately 80% of the cells
were transfected30,93.
2.2.8

Immunokinase assay
Activities of MLCK, AMPK, PKC, ZIPK, and Rho kinase were measured by an

immunokinase assay as previously described30,34,39,93-96. Muscle cells were washed one time with
PBS, and then were lysed with buffer containing 50 mM Tris-HCl (pH 7.5),150 mM NaCl, 0.1 %
SDS, 0.5% sodium deoxycholate, 1% NP-40, 10 mM sodium pyrophosphate, and protease
inhibitor cocktail (2 μl/ml, BD Biosciences). The homogenates were centrifuged at 10,000 rpm
for 10 min at 4 C. The supernatant containing cytosolic protein was transferred to a fresh tube
and 5 μl of the specific antibody was added to each tube and incubated for 2 h at 4 C.
At the end of two hours, Protein A/G agarose was added to each tube and the mixture was
reincubated at 4 C for overnight and washed 3 times with lysis buffer. The pellets were resuspended in 50 μl of kinase buffer containing 100 mM Tris-HCl (pH 7.4), 1 M KCl, 50 mM
MgCl2, 10 mM EDTA, and 1 mM DTT. Twenty microliters of the immunoprecipitates were
added to the reaction mixture containing 100 mM Tris-HCl (pH 7.4), 1 M KCl, 50 mM MgCl2, 1
mM DTT, 1 mM ATP, and 10 μCi of [γ-32P] ATP (3,000 Ci/mol) along with 5 μg of myelin basic
protein (for Rho kinase II, ZIPK an dPKC), or 1 µg purified recombinant MLCK (for AMPK),
followed by incubation for 15 min at 37 C. Phosphorylation of myelin basic protein or MLCK
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was absorbed onto phosphocellulose disks, and free radioactivity was removed by washing 3
times with 75 mM H3PO4. The amount of radioactivity on the disks was measured by liquid
scintillation. The results are expressed as counts per milligram protein per minute.
2.2.9

Cyclic GMP-dependent protein kinase (PKG) assay
PKG activity was measured by the method of Jiang et al

97

. One milliliter of cell

suspension was incubated in HEPES medium with 8-Br-cGMP for 90 s at 310C. The reaction was
stopped by rapid centrifugation, and the pellet was rinsed with a medium containing 50 mM TrisHCl (pH 7.4), 10 mM EDTA, 0.5 mM IBMX, 10 mM β-mercaptoethanol, and 100 mM NaCl and
homogenized in 0.5 ml ice-cold medium. The mixture was centrifuged at 48, 000 g for 15 min
and the supernatant was used as a source of protein kinaase. PKG activity was measured in a
volume of 60 µl containing 50 mM Tris, 10 mM MgCl2, 100 µM [32P]ATP, 50 µM synthetic
heptapeptide histone H2B [Arg-Lys-Arg-Ser-Arg-Ala-Glu (RKRSRAE)], and 0.25 mg/ml of
bovine serum albumin. The assay was done in the presence or absence of 10 µM of cGMP and 1
µM PKI (6-22 amide) and was initiated by the addition of 20 µl of cell supernatants (50 µg
protein) to the reaction mixture. PKG activity was calculated as pmoles/mg protein and expressed
as the ratio of activity in the presence or absence of 10 µM cGMP (-cGMP/+cGMP).
2.2.10 Western blot analysis
Muscle cells were solubilized in Triton X-100-based lysis buffer plus protease and
phosphatase inhibitors (100 μg/ml PMSF, 10 μg/ml aprotinin, 10 μg/ml leupeptin, 30 mM sodium
fluoride and 3 mM sodium vanadate). After centrifugation of the lysates at 20000 g for 10 min at
4 °C, the protein concentrations of the supernatant were determined with a Dc protein assay kit
from Bio-Rad. Equal amounts of proteins were fractionated by SDS/PAGE, and transferred on to
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nitrocellulose membrane. Blots were blocked in 5% (w/v) non-fat dried milk/TBS-T [tris-buffered
saline (pH 7.6) plus 0.1% Tween-20] for 1 h and then incubated overnight at 4 °C with various
primary antibodies in TBS-T plus 1% (w/v) non-fat dried milk (Table 2). After incubation for 1 h
with horseradish-peroxidase-conjugated corresponding secondary antibody (1:2000; 10 μg/ml,
Pierce) in TBS-T plus 1% (w/v) non-fat dried milk, immunoreactive proteins were visualized
using SuperSignal Femto maximum sensitivity substrate kit (Pierce). All washing steps were
performed with TBS-T. The protein bands were identified by enhanced chemiluminescence
reagent.
Quantification of protein bands obtained on western blot was done by densitometric
analysis of the Details view of the Odyssey software using the median method for calculation of
background. The average intensity obtained for each band was normalized to that of β-actin for
the same lane. The band intensity of each treatment was then calculated as a percent value of
normalized value of the control lane. The percent value of the control was used for statistical
analysis.
2.2.11 Radioimmunoassay for cGMP.
Cyclic GMP levels were measured by radioimmunoassay, as previously described

70

.

Suspensions of smooth muscle cells (106 cells/ml) were stimulated for 1 min with GSNO in the
presence of 100 µM IBMX, and the reaction was terminated with 10% trichloroacetic acid.
Samples were centrifuged, and the supernatant was extracted with diethyl ether and lyophilized.
Samples were resuspended in Na-acetate buffer (pH 6.2) followed by acetylation with
triethylamine-acetic anhydride for 10 min. cGMP was measured in duplicate using 100-µl
aliquots, and the results are expressed as picomoles per milligram of protein.
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Table 2. Primary antibodies. Primary antibodies and their catalogue number, company of
production, product size and dilution ratio.
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Product
Antibody

Catalog #

size

Company name

Dilution

(kDa)
AMPKα1 (C-20)

sc-19128

63

SANTA CRUZ

1/1000

MYLK (L-18)

sc-9452

210/135

SANTA CRUZ

1/1000

Rock-2 (H-85)

sc-5561

160

SANTA CRUZ

1/1000

ZIP-kinase (C-19)

sc-8161

52

SANTA CRUZ

1/1000

MYPT1 (N-15)

sc-17433

130

SANTA CRUZ

1/1000

MRCL3/MRLC2/MYL9 (FL-172)

sc-15370

20

SANTA CRUZ

1/1000

Telokin

sc-22226

17

SANTA CRUZ

1/1000

CPI-17 (N-20)

sc-17561

17

SANTA CRUZ

1/1000

PKC ε (17)

sc-56944

82

SANTA CRUZ

1/1000

PDE5

2395

100

CELL SIGNALING

1/1000

MRP5 (C-17)

sc-5780

185

SANTA CRUZ

1/1000

PKG

7721301

PROMEGA

1/1000

β-actin

AC1978

42

SIGMA

1/5000

Tropomyosin (FL-284)

sc-28543

35-45

SANTA CRUZ

1/1000

Caldesmon (H-300):

sc-15374

90-150

SANTA CRUZ

1/1000

Calponin 1 (CALP)

sc-58707

33-36

SANTA CRUZ

1/1000
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2.2.12 Phosphorylation of MLCK and AMPK

Phosphorylation of MLCK and AMPK was determined from the amount of
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P

incorporated into the enzyme after immunoprecipitation with MLCK or AMPK antibody
respectively. A 10 ml suspension of smooth-muscle cells (4×106 cells/ml) was prelabelled with
0.5 mCi/ml of [32P]Pi for 3 h. Samples (1 ml) were treated with ACh in the presence or absence
of various agents. The reaction was terminated with an equal volume of lysis buffer, containing
1% (v/v) Triton X-100, 0.5% SDS, 10 mM EDTA, 1 mM PMSF, 10 µg/ml leupeptin, 100 µg/ml
aprotinin, 10 mM sodium pyrophosphate, 50 mM NaF and 0.2 mM sodium vanadate. The cell
lysates were separated from the insoluble material by centrifugation at 13000 g for 15 min at 4
°C, precleared with 40 µl of Protein A–Sepharose and incubated with antibody to MLCK or
AMPK for 2 h at 4 °C. After addition of Protein A–Sepharose (40 µl), the lysates were incubated
for 1 h. The immunoprecipitates were washed five times with 1 ml of wash buffer containing 10
mM Tris/HCl (pH 7.4), 150 mM NaCl and 0.5% Triton X-100, and extracted with SDS sample
buffer. The samples were resolved by SDS/PAGE and
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P-labelled MLCK and AMPK were

visualized by autoradiography, and the amount of radioactivity in the bands was counted.

2.2.13 Assay for phosphodiesterase 5 (PDE5) activity
PDE5 activity was measured in immunoprecipitates of PDE5 by the method of Wyatt et
al.

98

. PDE5 was immunoprecipitated from lysates of dispersed gastric smooth-muscle cells

(3×106 cells/ml) using an anti-PDE5 antibody, and the immunoprecipitates were washed in a
solution of 50 mM Tris/HCl (pH 7.5), 200 mM NaCl and 5 mM EDTA. The immunoprecipitates
were then incubated for 15 min at 30 °C in a reaction mixture containing 100 mM Mes (pH 7.5),
10 mM EDTA, 0.1 M magnesium acetate, 0.9 mg/ml BSA, 20 µM cGMP and [3H] cGMP. The
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samples were boiled for 3 min, chilled for 3 min and then incubated at 30 °C for 10 min in 20
mM Tris/HCl (pH 7.5) containing 10 µl of C. atrox snake venom (10 µg/µl). The samples were
added to DEAE-Sephacel A-25 columns and the radioactivity in the effluent was counted. The
results were expressed as cpm/mg of protein.

2.2.14 Immunoblot analysis of MLC20 and CPI-17 phosphoproteins.
Phosphorylation of MLC20 and CPI-17 was determined by immunoblot analysis with
phosphospecific antibodies as described preciously
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. Muscle cells were treated with ACh or

Ca2+ for 30 s or 10 min and solubilized on ice in a medium containing 20 mM Tris·HCl (pH 8.0),
1 mM DTT, 100 mM NaCl, 0.5% SDS, 0.75% deoxycholate, 1 mM PMSF, 10 µg/ml leupeptin,
and 100 µg/ml aprotinin. The lysate proteins were resolved by SDS-PAGE and transferred onto
polyvinylidene difluoride membranes. The membranes were incubated for 12 h with
phosphospecific antibodies to MLC20 (Ser19) or CPI-17 (Thr38) and then incubated for 1 h with
horseradish peroxidase-conjugated secondary antibodies. The bands were identified by enhanced
chemiluminescence. Quantification of protein bands obtained on western blot was done by
densitometric analysis as described above.

2.2.15 Measurement of contraction and relaxation in dispersed smooth muscle cells
Contraction in freshly dispersed gastric circular smooth muscle cells was determined by
scanning micrometry93. An aliquot (0.4 ml) of cells containing approximately 104 cells/ml was
treated with 100 μl of medium containing acetylcholine (ACh, 0.1 µM) for 30 s or 10 min and the
reaction was terminated with 1% acrolein at a final concentration of 0.1%. Acrolein kills and
fixes cells without affecting the cell length.

The resting cell length was determined in control

experiments in which muscle cells were incubated with 100 l of 0.1% bovine serum albumin
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without the ACh.

The mean lengths of 50 muscle cells treated with various agonists was

measured by scanning micrometry and compared with the mean lengths of untreated cells. The
contractile response was expressed as the percent decrease in mean cell length from control cell
length.
Relaxation was measured in intact muscle cells contracted with ACh (0.1 µM). Muscle
cells were treated for 1 minute with GSNO followed by ACh for 30 s or 10 min. The reaction was
terminated with 1% acrolein. The length of 50 cells treated with acetylcholine was measured in
sequential microscopic fields by scanning micrometry. Relaxation was expressed as percent
increase in the length of cells contracted with ACh.

2.2.16 Transfection of cultured smooth muscle cells with MRP5 siRNA

Confluent smooth muscle cells in the first passage on six-well plates were transiently
transfected with the control vector or vector encoding MRP5 siRNA using Lipofectamine 2000
according to the manufacturer's instructions (Invitrogen). Briefly, 2 µg of the vector in 125 µl
Opti-MEM medium were mixed with 5 µl Lipofectamine 2000 in 125 µl Opti-MEM. The mixture
was incubated at room temperature for 20 min and added to wells containing 1.5 ml DMEM with
10% FBS for 1 day. The medium was then replaced with DMEM with 10% FBS plus antibiotics
for 2 days. Cells were maintained for a final 24 h in DMEM without FBS before experiments
were started.
2.3.

Experimental approach
1. We have used two approaches to determine the differences in smooth muscle

contraction and relaxation signaling pathways in antrum versus fundus parts of the stomach. In
the first approach, freshly dispersed muscle cells were used to examine expression of various
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proteins by western blot, enzyme activities by immuno kinase assay, protein phosphorylation, and
smooth muscle contraction and relaxation in response to various reagents.

In the second

approach, cultured muscle cells in the first passage were used for various molecular and
biochemical studies. The purity of cultured muscle cells was determined using markers for
smooth muscle, interstial cells of Cajal, enteric neurons and endothelial cells. Use of cultured
muscle cells is essential for mRNA expression by RT-PCR and real time PCR and for the
expression of phosphorylation-deficient mutants of telokin cDNAs.
2. Permeabilized muscle cells were used to preclude the effects of 8-Br-cGMP on
mechanisms upstream of Ca2+ generation.
3. The concentrations of inhibitors used in the present study was based on the previous
studies in smooth muscle cells and shown to be maximally effective in eliciting an inhibitory
response30,32-34,93.
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2.4

Statistical analysis
The results were expressed as means  S.E. of n experiments and analyzed for statistical

significance using Student‟s t-test for paired and unpaired values.

Each experiment was

performed on cells obtained from different animals. Differences among multiple groups were
tested using ANOVA and checked for significance using Fisher‟s protected least significant
difference test. A statistical software program was used (GraphPad software, San Diego, CA). A
probability of p<0.05 was considered significant.
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CHAPTER 3
DIFFERENTIAL EXPRESSION OF PROTEINS ASSOCIATED WITH THE
CONTRACTILE FILAMENTS IN SMOOTH MUSCLE OF ANTRUM AND FUNDUS

Previous studies using esophagus and lower esophageal sphincter as models of phasic and
tonic smooth muscle, respectively, have demonstrated that the expression of various contractile
proteins is tissue specific and related to the function of the muscle

99,100

. Initially, studies were

carried out to examine whether the expression of contractile proteins is different in muscle cells
from antrum and fundus and correlates with the phasic and tonic phenotypes of the muscle,
respectively.
The mRNA expression levels of various contractile proteins were analyzed using specific
primers by both RT-PCR and qRT-PCR in cultured muscle cells in the first passage. As shown
previously
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, the use of confluent cultures of smooth muscle in the first passage ensured the

absence of neural, endothelial, or interstitial cell contaminants.
Specific primers were designed based on known sequences in rabbit, if available, or
based on the conserved sequences in human, rat, and mouse cDNAs (Table 1). In an initial
evaluation, the accuracy of the designed primers was evaluated with agarose gels followed by
sequencing of amplicons generated with the primers. Moreover, the formation of primer-dimers
and the PCR efficiency of the primer sets were examined. Both the size and the sequence of all
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real time RT-PCR amplicons were confirmed. Melt curve analyses showed single peaks for all
samples. The PCR efficiencies were calculated from standard curves. The values of the PCR
efficiencies were higher than 90%, and the difference among them was not greater than 5%.
-ΔΔCT

These findings validated the design of primers and satisfied the requirements for use of the 2
quantification method, described previously in the Materials and Methods section.
GAPDH expression was chosen to normalize the expression of the contractile proteins.
The GAPDH amplicon was utilized to normalize and calculate the quantitative expression of
various genes. Thus, a quantitative comparison between antrum and fundus tissue was
-ΔΔCT

calculated with the 2
3.1

method by normalizing the ΔCT counts to GAPDH expression.

Actins
Expression of six different isoforms of actin with similar levels of acto-myosin ATPase

activating property has been demonstrated in smooth muscle tissues. α- and γ-actin isoforms were
found to be located primarily within the contractile apparatus, while β-actin is a highly conserved
protein and shown to be the cytoskeletal actin isoform. The expression of α-actin is predominant
in vascular smooth muscles, while expression of γ-actin is predominant in visceral smooth
muscles. The expression of α, β and γ-actin isoforms were examined in antrum and fundus
smooth muscle using isoform-specific primers (Table 1). A PCR product with predicted size was
detected for α-actin (97bp), γ- actin (70bp) or β-actin (100bp) in muscle cells from both antrum
and fundus of rabbit stomach. The differences in the expression levels were analyzed by qRTPCR. The results showed that expression of α-actin was 11-fold (p<0.001, n=3) greater in muscle
cells from fundus compared to muscle cells from antrum, whereas the expression of γ-actin was
~3-fold (p<0.05, n=3) greater in muscle cells from antrum than fundus (Figure 1). There was no
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significant difference in the expression of β-actin between muscle cells from antrum and fundus
(Figure 1).
3.2

Tropomyosins
Expression two different isoforms of tropomyosin has been demonstrated in smooth

muscle tissues
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. Expression of both -tropomyosin and β-tropomyosin was measured in

muscle cells of antrum and fundus. The differences in the expression levels were analyzed by
qRT-PCR. The results showed that expression of α-tropomyosin was 5-fold greater, and βtropomyosin was 2-fold greater in muscle cells from antrum compared to fundus (Figure 2).
Expression of tropomyosin was also examined in the two regions of the stomach by
western blot analysis using an antibody that recognizes all the isoforms of tropomyosin. Results
showed expression of 2 protein bands with ~45 kDa in the muscle cells from antrum, but only
one band in muscle cells from fundus. The molecular weight of the protein bands corresponds to
the expected molecular weight of tropomyosin isoforms (35-45 kDa). Comparing the densities of
protein bands in the two regions revealed higher expression in muscle cells from antrum
compared to fundus and this is consistent with higher expression of mRNA (Figure 2).
3.3

Calponin and Caldesmon
Calponin and caldesmon are thin filament associated proteins that were shown to regulate

smooth muscle contraction. They are differentially expressed in phasic (e.g., esophagus) versus
tonic (e.g., lower esophageal sphincter) smooth muscles99,100. Expression of h-caldesmon and h1calponin was analyzed by qRT-PCR in muscle cells from antrum and fundus. The results showed
that the expression of h1-calponin was 2-fold higher and h-caldesmon was 3-fold higher (p<0.05,
n=3) in muscle cells from antrum compared to fundus. Western blot analysis using antibody to
h1-calponin or h-caldesmon demonstrated expression of h1-calponin (~35 kDa) and h-caldemon
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(~100 kDa) in both antrum and fundus, and confirmed higher expression in muscle cells from
antrum compared to fundus (Figure 3).
3.4

Smoothelin
Expression two different isoforms of smoothelin has been demonstrated in smooth

muscle tissues 103. Expression of smoothelin-A isoform was found to be predominant in visceral
smooth muscle cells, whereas expression of smoothelin-B isoform was found to be predominant
in vascular smooth muscle. Expression of smoothelin-A and -B isoforms was analyzed by qRTPCR in muscle cells from antrum and fundus. The results showed that expression of smoothelinA was 4-fold (p<0.05, n=3) higher in muscle cells from antrum compared to fundus, whereas
expression of smoothelin-B was 3-fold higher (p<0.05, n=3) in fundus compared to antrum
(Figure 4).
3.5

Myosin heavy chain
The smooth muscle myosin is a hexamer with a pair of heavy chains (220 kDa), a pair of

20 kDa regulatory light chains or myosin light chains (MLC20) and a pair of 17 kDa essential
light chains. Myosin heavy chain is encoded by a single gene, but alternative splicing at two sites
can create four different variants of this ~ 200 kDa polypeptide (SM1, SM2, SM-A and SM-B
isoforms). Expression of myosin heavy chain isoforms (SM1, SM2, SM-A and SM-B) was
determined by RT-PCR. PCR product of expected size was obtained using specific primers for
SM1 (330 bp) and SM2 (291 bp) only in antrum, and the expression of SM1 appears to be greater
than SM2 (Figure 5). However, no detectable PCR product was obtained in fundus using same
primers for SM1 and SM2. Expression of SM-A and SM-B was also analyzed using specific
primers for SM-A and SM-B. Expression of both SM-A (197 bp) and SM-B (218 bp) isoforms
was detected in fundus, but only SM-B was detected in antrum (Figures 5). Expression of SM-B
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appears to be higher in muscle cells from antrum compared to fundus. The results are consistent
with the higher expression of SM-B isoform in phasic muscle 75.
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Figure 1. Expression of α-, β-, and γ- actin. Total RNA isolated from cultured (first passage)
gastric circular muscle cells from antrum and fundus using RNAqueous prep kits (Ambion,
Austin, Tx) was reverse transcribed using 2 µg of total RNA using qScript cDNA prep kits
(Quanta, Gaithersburg, MD). The cDNA was amplified with specific primers for α-, β-, and γactin. PCR products of expected size (97 bp, 100 bp, and 70 bp) were obtained with α-, β-, and γactin primers, respectively. The sequences of specific primers are listed in Table 1. Quantitative
real-time polymerase chain reaction (qRT-PCR) was used to measure RNA levels of -actin, γactin and β-actin. For each cDNA sample, real-time PCR was conducted in a 20 μl reaction
TM

volume containing Quantitect

SYBRgreen PCR Mastermix (Qiagen, Mississauga, ON). Real-

time PCR reactions were performed in triplicate. Each primer set generated only one PCR
product, and the identity and integrity of these products were confirmed by electrophoresis in
agarose gel in the presence of ethidium bromide and sequencing of the individual bands (inset:
representative PCR products of -actin, γ-actin and β-actin). Standard curves for each amplicon
were generated from a dilution series of cDNA and results were quantified and reported using the
−ΔΔCT

2

method based on GAPDH amplification. GAPDH amplicon thresholds remained constant.

Relative quantification of a target gene in relation to reference gene was calculated on the basis of
delta delta CT values. Results demonstrated that α-actin mRNA levels are higher, while γ-actin
mRNA levels are lower in fundus compared to antrum. β-actin mRNA levels were similar in
antrum and fundus. Values represent the means SEM of 3 separate experiments. *p<0.05
versus fundus; **p<0.001 versus antrum
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Figure 2. Expression of α- and β-tropomyosin. Total RNA was isolated from cultured (first
passage) muscle cells from antrum and fundus using RNAqueous prep kits (Ambion, Austin, Tx)
was reverse transcribed using 2 µg of total RNA using qScript cDNA prep kits (Quanta,
Gaithersburg, MD). The cDNA was amplified with specific primers for α- or β-tropomyosin.
PCR products of expected size (75bp, and 67bp,) were obtained with α-or β-tropomyosin primers
respectively. The sequences of specific primers are listed in Table 1. Quantitative real-time
polymerase chain reaction (qRT-PCR) was used to measure RNA levels of - or β-tropomyosin.
For each cDNA sample, real-time PCR was conducted in a 20 μl reaction volume containing
TM

Quantitect

SYBRgreen PCR Mastermix (Qiagen, Mississauga, ON). Real-time PCR reactions

were performed in triplicate. Each primer set generated only one PCR product, and the identity
and integrity of these products were confirmed by electrophoresis in agarose gel in the presence
of ethidium bromide and sequencing of the individual bands. Standard curves for each amplicon
were generated from a dilution series of cDNA and results were quantified and reported using the
−ΔΔCT

2

method based on GAPDH amplification. GAPDH amplicon thresholds remained constant.

Relative quantification of a target gene in relation to reference gene was calculated on the basis of
delta delta CT values. Results demonstrated that both α- and β-tropomyosin mRNA levels are
higher in antrum compared to fundus. Inset: Representative western blot results of tropomyosin
expression. Cell lysates containing equal amounts of total proteins were separated with SDSPAGE and expression of tropomyosin was analyzed using an antibody that recognizes all the
isoforms of tropomyosin. Values represent the means SEM of 3 separate experiments. *p<0.05
versus fundus; **p<0.001 versus fundus.
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Figure 3. Expression of h1-calponin and h-caldesmon. Total RNA isolated from cultured (first
passage) muscle cells from antrum and fundus was reverse transcribed using 2 µg of total RNA.
The cDNA was amplified with specific primers for h1-clponin and h-caldesmon. PCR products
of expected size (86 bp and 61 bp) were obtained with h1-clponin and h-caldesmon primers
respectively. The sequences of specific primers are listed in Table 1. Quantitative real-time
polymerase chain reaction (qRT-PCR) was used to measure RNA levels of h1-clponin and hcaldesmon. For each cDNA sample, real-time PCR was conducted in a 20 μl reaction volume
TM

containing Quantitect

SYBRgreen PCR Mastermix. Real-time PCR reactions were performed

in triplicate. Each primer set generated only one PCR product, and the identity and integrity of
these products were confirmed by electrophoresis in agarose gel in the presence of ethidium
bromide and sequencing of the individual bands.

Standard curves for each amplicon were

generated from a dilution series of cDNA and results were quantified and reported using the
−ΔΔCT

2

method based on GAPDH amplification. Relative quantification of a target gene in

relation to reference gene was calculated on the basis of delta delta CT values.

Results

demonstrated that both h1-calponin and h-caldesmon levels are higher in antrum compared to
fundus. Inset: Representative western blot results of calponin and caldesmon expression. Cell
lysates containing equal amounts of total proteins were separated with SDS-PAGE and
expression of calponin or caldesmon was analyzed using selective antibody. Values represent the
means SEM of 3 separate experiments. *p<0.05 versus fundus.
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Figure 4. Expression of smoothelin-A and smoothelin-B. Total RNA isolated from cultured
(first passage) muscle cells from antrum and fundus was reverse transcribed using 2 µg of total
RNA. The cDNA was amplified with specific primers for smoothelin-A and smoothelin-B. PCR
products of expected size (107 bp and 65 bp) were obtained with smoothelin-A and smoothelin-B
primers, respectively. The sequences of specific primers are listed in Table 1. Quantitative realtime polymerase chain reaction (qRT-PCR) was used to measure RNA levels of smoothelin-A
and smoothelin-B. For each cDNA sample, real-time PCR was conducted in a 20 μl reaction
TM

volume containing Quantitect

SYBRgreen PCR Mastermix. Real-time PCR reactions were

performed in triplicate. Each primer set generated only one PCR product, and the identity and
integrity of these products were confirmed by electrophoresis by electrophoresis in agarose gel in
the presence of ethidium bromide and sequencing of the individual bands. Standard curves for
each amplicon were generated from a dilution series of cDNA and results were quantified and
−ΔΔCT

reported using the 2

method based on GAPDH amplification. Relative quantification of a

target gene in relation to reference gene was calculated on the basis of delta delta CT values.
Results demonstrated that expression of smoothelin-A is higher in antrum compared to fundus,
whereas expression of smoothelin-B is higher in fundus compared to antrum. Values represent
the means SEM of 3 separate experiments. **p<0.001 versus fundus for smoothelin-A, and
versus antrum for smoothelin-B.
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Figure 5. Expression of myosin heavy chain isoforms (SM1/2 and SMA/B). Total RNA
isolated from cultured (first passage) gastric circular muscle cells from antrum and fundus was
reverse transcribed using 2 µg of total RNA. The cDNA was amplified with specific primers for
SM1/2 or SM-A/SM-B. PCR products of expected size (330/291 bp and 197/218 bp) were
obtained with SM1/2 or SM-A/SM-B primers respectively. The sequences of specific primers are
listed in Table 1. Primers for SM1/2 generated two PCR products only in antrum, whereas
primers for SM-A/SM-B generated one PCR product, corresponding to SM-B, in antrum and 2
products corresponding to both SM-A and SM-B isoforms in fundus.

Results show

representative PCR products of myosin heavy chain isoforms separated by electrophoresis in
agarose gel in the presence of ethidium bromide and visualized by a ChemiImager Fluorescence
system.
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CHAPTER 4
DIFFERENTIAL REGULATION OF MLCK ACTIVITY AND INITIAL MUSCLE
CONTRACTION IN ANTRUM AND FUNDUS

In gastrointestinal smooth muscle, contraction-induced by Gq-coupled receptor agonists
(e.g., acetylcholine) consists of a transient Ca2+-dependent phase and reflects sequential
activation of PLC-β1, IP3-depedent Ca2+ release, Ca2+/CaM-dependent activation of MLCK and
phosphorylation of Ser19 on MLC20, leading to interaction of actin and myosin and muscle
contraction. The levels of MLC20 phosphorylation and contraction are dependent on relative
activities of MLCK and MLCP. Ca2+/CaM complex stimulates MLCK activity and the affinity of
MLCK for Ca2+/CaM is regulated by several mechanisms. Recent studies have demonstrated that
agonist-induced MLCK activity is regulated by AMPK in vascular smooth muscle. Stimulation
of AMPK activity was mediated by an upstream Ca2+/CaM-dependent protein kinase kinase-β
(CaMKK-β), which phosphorylates AMPK at Thr172 and thus stimulates AMPK activity104. We
postulated that the rapid termination of contraction and MLCK activity by AMPK could
contribute to the phasic phenotype of antrum.
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4.1

Expression and activation of AMPK
Expression of AMPK, by both qRT-PCR and western blot, and stimulation of AMPK

activity in response to ACh (0.1µM) and depolarizing concentrations of KCl (20 mM) were
determined in muscle cells from antrum and fundus. AMPK1 mRNA was expressed in muscle
cells from both antrum and fundus and the expression was 3-fold (p<0.001, n=3) greater in
antrum compared to fundus (figure 6). AMPK protein expression was examined in the two
regions of the stomach by western blot using selective antibody to AMPKα1, the smooth muscle
predominant isoform105. The results confirmed the expression of AMPKα1 of predicted size (63
kDa) in the homogenates of smooth muscle cells of both antrum and fundus. Comparing the
densities of protein bands in the two regions revealed a ~ 6-fold higher expression of AMPK in
antrum compared to fundus (p<0.001, n=4) and this is consistent with the higher expression of
AMPK mRNA in antrum compared to fundus (figure 6).
Basal and agonist-stimulated AMPK activity was measured by immunokinase assay using
recombinant MLCK as substrate. Although, the expression levels are different, basal AMPK
activity was not significantly different in antrum (7561860 cpm/mg protein) and fundus
(5741602 cpm/mg protein). Treatment of freshly dispersed muscle cells with ACh (0.1 µM)
significantly increased AMPK activity in antrum (56734% increase; 443573672 cpm/mg
protein above basal level), but not in fundus (Figure 7). The results are consistent with higher
expression of AMPK in antrum.
Previous studies have shown that AMPK activity is stimulated by several upstream
kinases including CaMKK-β, LKB1, and TAK1. CaMKK-β links AMPK activity with increase
in intracellular Ca2+. Freshly dispersed smooth muscle cells from both antrum and fundus
were treated with ACh (0.1 M) in the presence or absence of STO609 (10 µM), a selective
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inhibitor of CaMKKβ, BAPTA (10 µM), a selective Ca2+ chelator, or calmidazolium (10µM),
a selective CaM antagonist.
The increase in ACh-induced AMPK activity was blocked by pre-treatment of cells
with STO609 (836% inhibition, p<0.001, n=4), BAPTA (7712% inhibition), or
calmidazolum ( 898% inhibition) (Figures 7, 8, 9). These results suggest that stimulation of
AMPK activity in muscle cells from antrum is mediated by CaMKKβ in a Ca2+/calmodulindependent manner.
To examine whether stimulation of AMPK activity can be mediated by an increase
intracellular Ca2+ without receptor activation, muscle cells were treated with depolarizing
concentrations of KCl (20 mM ) for 30 s and AMPK activity was measured. KCl significantly
increased AMPK activity in antrum (51326% increase; 38801 3120 cpm/mg protein above
basal level, but not in fundus (Figure 10). The extent of stimulation in antrum was similar to
that induced by ACh. KCl-induced AMPK activity was blocked by pre-treatment of cells with
BAPTA (898% inhibition, p<0.001) or calmidazolium (826% inhibition) (Figures 10 and
11).
Further evidence for the involvement of phosphorylation in the stimulation of AMPK
activity was obtained by measurement of AMPK phosphorylation in cells labeled with [32P]Pi
followed by immunoblot with AMPK1 antibody in both antrum and fundus. ACh induced
significant phosphorylation of AMPK in muscle cell from antrum (2156402 cpm/mg protein),
but had no effect in muscle cells from fundus (Figure 12).
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Figure 6. Expression of AMPK1. Total RNA isolated from cultured (first passage) muscle
cells from antrum and fundus was reverse transcribed using 2 µg of total RNA. The cDNA was
amplified with specific primers for AMPKα1. The sequences of specific primers are listed in
Table 1. Quantitative real-time polymerase chain reaction (qRT-PCR) was used to measure RNA
levels of AMPK1. For each cDNA sample, real-time PCR was conducted in a 20 μl reaction
volume containing TaqMan Gene Expression master Mix. Real-time PCR reactions were
performed in triplicate. Each primer set generated only one PCR product (63 bp), and the identity
and integrity of these products were confirmed by electrophoresis in agarose gel in the presence
of ethidium bromide and sequencing of the individual bands.

Relative quantification of a target

gene in relation to reference gene was calculated on the basis of delta delta CT values. Results
demonstrated that mRNA levels of AMPK1 are higher in antrum compared to fundus. Inset:
Representative western blot results of AMPK1 expression.

Cell lysates containing equal

amounts of total proteins were separated with SDS-PAGE and expression of AMPK1 was
analyzed using selective antibody for AMPK1. Membranes were reblotted to measure β-actin.
Protein bands visualized with enhanced chemiluminescence, images were quantified and
densitometric values were calculated after normalization to β-actin density. Results are expressed
as fold increase over the expression of AMPK1 in fundus. Values represent the means SEM
of 3 separate experiments. **p<0.001 versus fundus.
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Figure 7. Stimulation of AMPK activity by ACh and sensitivity to CAMKKβ antagonist.
One milliliter of cell suspension (2 x 106 cells/ml) freshly dispersed muscle cells from antrum and
fundus were treated with ACh (0.1 µM) for 30 s in the presence or absence of STO609 (1 µM), a
selective inhibitor of CaMKKβ. The cells were homogenized in the lysis buffer and the protein
content in the supernatants was measured.

AMPK was immunoprecipitated from lysates

containing equal amounts of protein and the activity was measured in immunoprecipitates using
purified recombinant MLCK as substrate and [32P]ATP. The amount of radioactivity absorbed
onto phosphocellulose disks reflecting kinase activity was measured by liquid scintillation and
the results are expressed as counts per milligram protein per minute. ACh stimulated AMPK
activity selectively in antrum and the stimulation was blocked by pretreatment of cells with
STO609. Values represent the means SEM of 4-5 separate experiments. **p<0.001 versus
basal activity in the absence of ACh.
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Figure 8. Ca2+-dependent stimulation of AMPK activity by ACh. One milliliter of cell
suspension (2 x 106 cells/ml) freshly dispersed muscle cells from antrum and fundus were treated
with ACh (0.1 µM) for 30 s in the presence or absence of BAPTA (10 µM), an intracellular Ca2+
chelator.

The cells were homogenized in the lysis buffer and the protein content in the

supernatants was measured.

AMPK was immunoprecipitated from lysates containing equal

amounts of protein and the activity was measured in immunoprecipitates using purified
recombinant MLCK as substrate and [32P]ATP. The amount of radioactivity absorbed onto
phosphocellulose disks reflecting kinase activity was measured by liquid scintillation and the
results are expressed as counts per milligram protein per minute. ACh stimulated AMPK activity
selectively in antrum and the stimulation was blocked by pretreatment of cells with BAPTA.
Values represent the means SEM of 4-5 separate experiments. **p<0.001 significant increase
above basal activity induced by ACh; ##p<0.05 significant inhibition of ACh-stimulated activity
by BAPTA.
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Figure 9. Calmodulin-dependent stimulation of AMPK activity by ACh. One milliliter of
cell suspension (2 x 106 cells/ml) freshly dispersed muscle cells from antrum and fundus were
treated with ACh (0.1 µM) for 30 s in the presence or absence of calmidazolium (10 µM), a
calmodulin antagonist. The cells were homogenized in the lysis buffer and the protein content in
the supernatants was measured. AMPK was immunoprecipitated from lysates containing equal
amounts of protein and the activity was measured in immunoprecipitates using purified
recombinant MLCK as substrate and [32P]ATP. The amount of radioactivity absorbed onto
phosphocellulose disks reflecting kinase activity was measured by liquid scintillation and the
results are expressed as counts per milligram protein per minute. ACh stimulated AMPK activity
selectively in antrum and the stimulation was blocked by pretreatment of cells with
calmidazolium. Values represent the means SEM of 4-5 separate experiments. **p<0.001
significant increase above basal activity induced by ACh; ##p<0.05 significant inhibition of
ACh-stimulated activity by calmidazolium.
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Figure 10. Ca2+-dependent stimulation of AMPK activity by KCl. One milliliter of cell
suspension (2 x 106 cells/ml) freshly dispersed muscle cells from antrum and fundus were treated
with KCl (20 mM) for 30 s in the presence or absence of BAPTA (10 µM), an intracellular Ca2+
chelator.

The cells were homogenized in the lysis buffer and the protein content in the

supernatants was measured.

AMPK was immunoprecipitated from lysates containing equal

amounts of protein and the activity was measured in immunoprecipitates using purified
recombinant MLCK as substrate and [32P]ATP. The amount of radioactivity absorbed onto
phosphocellulose disks reflecting kinase activity was measured by liquid scintillation and the
results are expressed as counts per milligram protein per minute. KCl stimulated AMPK activity
selectively in antrum and the stimulation was blocked by pretreatment of cells with BAPTA.
Values represent the means SEM of 4-5 separate experiments. **p<0.001 significant increase
above basal activity induced by KCl; ##p<0.05 significant inhibition of KCl-stimulated activity
by BAPTA.
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Figure 11. Calmodulin-dependent stimulation of AMPK activity by KCl. One milliliter of
cell suspension (2 x 106 cells/ml) freshly dispersed muscle cells from antrum and fundus were
treated with KCl (20 mM) for 30 s in the presence or absence of calmidazolium (10 µM), a
calmodulin antagonist. The cells were homogenized in the lysis buffer and the protein content in
the supernatants was measured. AMPK was immunoprecipitated from lysates containing equal
amounts of protein and the activity was measured in immunoprecipitates using purified
recombinant MLCK as substrate and [32P]ATP. The amount of radioactivity absorbed onto
phosphocellulose disks reflecting kinase activity was measured by liquid scintillation and the
results are expressed as counts per milligram protein per minute. KCl stimulated AMPK activity
selectively in antrum and the stimulation was blocked by pretreatment of cells with
calmidazolium. Values represent the means SEM of 4-5 separate experiments. **p<0.001
significant increase above basal activity induced by KCl; ##p<0.05 significant inhibition of KClstimulated activity by calmidazolium.
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Figure 12. Phosphorylation of AMPK by ACh. Ten milliliter of cell suspension (2 x 106
cells/ml) freshly dispersed muscle cells from antrum and fundus were labeled with

32

P and the

cells were incubated with ACh for 30s. AMPK was immunoprecipitated from the cell lysates
containing equal amount of protein, extracted with Laemmeli buffer and separated by
electrophoresis on SDS-PAGE. Phosphorylated AMPK was visualized by autoradiography, and
the amount of radioactivity in the protein band was measured. The results are expressed as counts
per milligram protein per minute. Values represent the means SEM of 3 separate experiments.
**p<0.001 significant increase in phosphorylation above basal level induced by ACh.
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4.2

Feedback inhibition of MLCK activity
MLCK is the main enzyme responsible for MLC20 phosphorylation, and thus smooth

muscle contraction.

Expression of MLCK, by both qRT-PCR and western blot, and stimulation

of MLCK activity in response to ACh (0.1µM) were determined in muscle cells from antrum and
fundus. MLCK mRNA was expressed in muscle cells from both antrum and fundus, and the
expression was 3-fold higher (p<0.05 n=3) in antrum compared to fundus (Figure 13). MLCK
protein expression was examined in the two regions of the stomach by western blot using
selective antibody to MLCK. Results confirmed the expression of MLCK of predicted size (135
kDa) in the homogenates of smooth muscle cells from both antrum and fundus (Figure 13).
Comparing the densities of protein bands in the two regions revealed that there was nearly 2-fold
higher expression MLCK in muscle cells from antrum compared to fundus.
Basal and agonist-stimulated MLCK activity was measured by immunokinase assay using
MLC20 as substrate. Basal MLCK activity was not significantly different in antrum (1249116
cpm/mg protein) and fundus (1464236 cpm/mg protein). Treatment of freshly dispersed muscle
cells with ACh (0.1 µM) significantly increased MLCK activity in antrum (94356% increase,
127211038 cpm/mg protein above basal level, p<0.001, n=4) and fundus (82156% increase;
120451306 cpm/mg protein above basal level, p<0.001, n=4) (Figure 14).
Despite higher expression of MLCK in antrum, agonist-stimulated MLCK activity in antrum and
fundus was similar. This raised the possibility that MLCK activity might be negatively regulated
in antrum via a feedback mechanism involving AMPK. To examine this notion, ACh-stimulated
MLCK activity was measured in the presence of STO609, an inhibitor of CaMKK/AMPK
pathway. ACh-stimulated MLCK activity was significantly augmented (19435% increase above
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ACh treatment alone, p<0.001, n=4) in the presence of STO609 in muscle cells from antrum.
STO609 had no effect on ACh-stimulated MLCK activity in muscle cells from fundus (Figure
14). These results suggest that MLCK activity is negatively regulated in a feedback mechanism
via CaMKKβ/AMPK pathway in antrum, but not in fundus. The results are consistent with the
higher expression and activation of AMPK in antrum.
Further evidence for the involvement of AMPK in the regulation of MLCK activity was
obtained by measurement of MLCK phosphorylation in cells labeled with [32P]Pi followed by
immunoblot with MLCK antibody in both antrum and fundus.

ACh induced significant

phosphorylation of MLCK in muscle cell from antrum (3562564 cpm/mg protein), but had no
effect in muscle cells from fundus (Fig 15).
4.3

Regulation of initial muscle contraction by CaMKKβ/AMPK pathway
The inhibition of MLCK activity by AMPK in antrum muscle could contribute to its

phasic phenotype. To examine the involvement of CaMKK/AMPK pathway in the regulation of
muscle contraction, muscle cells from antrum and fundus were treated with different
concentrations of ACh for 30 s in the presence or absence of STO609 (10µM) and the decrease in
cell length was measured by scanning micrometry. Previous studies in gastrointestinal smooth
muscle have demonstrated that the contractile response at 30 s reflects Ca2+/CaM-depedent
activation of MLCK. Control cell length in muscle cells from antrum and fundus are similar
(953 µm in antrum and 1025 µm in fundus). ACh caused contraction that was concentrationdependent with an EC50 of 21 nM in antrum and 32 nM in fundus and the maximal response to
0.1 µM of ACh was similar in antrum and fundus (272% decrease in cell length in antrum and
283% decrease in cell length in fundus) (Figure 16). However, pretreatment of cells with
STO609 significantly augmented ACh-induced contraction in muscle cells from antrum and
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shifted the concentration-response curve to the left (EC50 0.090.06 nM). In contrast, STO609
had no effect on contraction in fundus. The results are consistent with the selective augmentation
of MLCK activity by STO609 in muscle cells from antrum, and further confirm the inhibitory
regulation of MLCK activity by AMPK.
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Figure 13. Expression of MLCK. Total RNA isolated from cultured (first passage) muscle
cells from antrum and fundus was reverse transcribed using 2 µg of total RNA. The cDNA was
amplified with specific primers for MLCK. The sequences of specific primers are listed in Table
1. Quantitative real-time polymerase chain reaction (qRT-PCR) was used to measure RNA levels
of MLCK. For each cDNA sample, real-time PCR was conducted in a 20 μl reaction volume
containing TaqMan GeneExpression Master Mix. Real-time PCR reactions were performed in
triplicate. Each primer set generated only one PCR product (71 bp), and the identity and integrity
of these products were confirmed by electrophoresis in agarose gel in the presence of ethidium
bromide and sequencing of the individual bands.

Relative quantification of a target gene in

relation to reference gene was calculated on the basis of delta delta CT values.

Results

demonstrated that mRNA levels of MLCK are higher in antrum compared to fundus. Inset:
Representative western blot results of MLCK expression. Cell lysates containing equal amounts
of total proteins were separated with SDS-PAGE and expression of MLCK was analyzed using
selective antibody for MLCK. Membranes were reblotted to measure β-actin. Protein bands were
visualized with enhanced chemiluminescence, images were quantified and densitometric values
were calculated after normalization to β-actin density. Results are expressed as fold increase over
the expression of MLCK in fundus.

Values represent the means SEM of 3 separate

experiments. *p<0.05 versus fundus.
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Figure 14. Stimulation of MLCK activity by ACh and sensitivity to CAMKKβ antagonist.
One milliliter of cell suspension (2 x 106 cells/ml) freshly dispersed muscle cells from antrum and
fundus were treated with ACh (0.1 µM) for 30 s in the presence or absence of STO609 (1 µM), a
selective inhibitor of CaMKKβ/AMPK pathway. The cells were homogenized in the lysis buffer
and the protein content in the supernatants was measured. MLCK was immunoprecipitated from
lysates containing equal amount of protein and the activity was measured in immunoprecipitates
using MLC20 as substrate and [32P] ATP.

The amount of radioactivity absorbed onto

phosphocellulose disks reflecting kinase activity was measured by liquid scintillation and the
results are expressed as counts per milligram protein per minute. ACh stimulated MLCK activity
in antrum and fundus. Stimulation of MLCK activity was augmented in antrum by pretreatment
of cells with STO609, suggesting feedback inhibition of MLCK activity selectively in antrum.
Values represent the means SEM of 4-5 separate experiments. **p<0.001 significant increase in
activity above basal level induced by ACh; ##p<0.05 significant augmentation of ACh-stimulated
MLCK activity by STO609.
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Figure 15. Phosphorylation of MLCK by ACh. Ten milliliter of cell suspension (2 x 106
cells/ml) of freshly dispersed muscle cells from antrum and fundus were labeled with 32P and the
cells were incubated with ACh for 30s. MLCK was immunoprecipitated from the cell lysates
containing equal amount of protein, extracted with Laemmeli buffer and separated by
electrophoresis on SDS-PAGE. Phosphorylated MLCK was visualized by autoradiography, and
the amount of radioactivity in the protein band was measured. The results are expressed as counts
per milligram protein per minute. Values represent the means SEM of 3 separate experiments.
**p<0.001 significant increase in phosphorylation above basal level induced by ACh.
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Figure 16. Effect of STO609 on ACh-induced muscle contraction. Contraction of dispersed
muscle cells from antrum and fundus was measured by scanning micrometry in response to
different concentrations of ACh in the presence or absence of STO609 (10 µM). Cells were
treated with ACh for 30s and pretreated with STO609 for 10 min. Contraction was expressed as
percent decrease in cell length from control cell length: control length of muscle cells from
antrum 953 µm; control length of muscle cells from fundus 1025 µm. ACh caused contraction
that was concentration-dependent in both antrum and fundus and the maximal response to 0.1 µM
of ACh was similar in antrum and fundus (272% decrease in cell length in antrum and 283%
decrease in cell length in fundus). STO609 significantly augmented ACh-induced contraction in
muscle cells from antrum, but had no effect on contraction in fundus. Values represent the means
SEM of 4 separate experiments. *p<0.05 significant increase in contraction by STO609.
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CHPATER 5
DIFFERENTIAL REGULATION OF MLCP ACTIVITY AND SUSTAINED MUSCLE
CONTRACTION IN ANTRUM AND FUNDUS

In smooth muscle, inhibition of MLCP activity and sustained MLC20 phosphorylation by
contractile agonists reflect activation of RhoA via G13 and/or Gq. The pathways that lead to
inhibition of MLCP involve phosphorylation of the regulatory subunit of MLCP (MYPT1) via
Rho kinase and phosphorylation of CPI-17, an endogenous inhibitor of MLCP, via PKC. A role
for ZIPK has also been suggested in the phosphorylation of MYPT1. We postulated that the
higher expression and/or activation of Rho kinase/MYPT1 and PKC/CPI-17 pathways leading to
sustained MLC20 phosphorylaiton could contribute to the tonic phenotype of fundus.
5.1

Rho kinase expression and activity
Expression of Rho kinase, by both qRT-PCR and western blot, and stimulation of Rho

kinase activity in response to ACh (0.1µM) were determined in muscle cells from antrum and
fundus. Rho kinase mRNA was expressed in both antrum and fundus and the expression was 3fold (p<0.05, n=3) greater in fundus compared to antrum (Figure 17). Rho kinase protein
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expression was examined in the two regions of the stomach by western blot using selective
antibody to Rho kinase II, the smooth muscle predominant isoform

32

. Results confirmed the

expression of Rho kinase of predicted size (150 kDa) in the homogenates of smooth muscle cells
from both antrum and fundus. Comparing the densities of protein bands in the two regions
revealed higher expression of Rho kinase in fundus compared to antrum (p<0.001, n=4) and this
is consistent with higher expression of Rho kinase mRNA in fundus compared to antrum (Figure
17).
To determine whether Rho kinase activity level correlates well with its expression profile
and thus with the contractile phenotypes in the fundus vs. antrum, freshly dispersed smooth
muscle cells from both parts of the stomach were treated with 0.1µM ACh, a Gαq/13-coupled
receptor agonist, for 10 min, and basal and agonist-stimulated Rho kinase activity was measured
by immunokinase assay using recombinant myelin basic protein as substrate. Although, the
expression levels are different, basal Rho kinase activity was not significantly different in antrum
(3242367 cpm/mg protein) and fundus (4364503 cpm/mg protein). Treatment of freshly
dispersed muscle cells with ACh significantly increased Rho kinase activity in antrum (23815%
increase; 7730821 cpm/mg protein above basal level, p<0.001, n=5) and fundus (36221%
increase; 158201423 cpm/mg protein above basal level, p<0.001, n=5) (Figure 18). Consistent
with the greater expression of Rho kinase in fundus, agonist-stimulated Rho kinase activity was
significantly higher in fundus compared to antrum. Y27632, a selective blocker of Rho kinase,
significantly inhibited stimulation of Rho kinase activity in both antrum (904% inhibition,
p<0.001, n=5) fundus (965 % inhibition, p<0.001, n=5) (Figure 18).
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Figure 17. Expression of Rho kinase II. Total RNA isolated from cultured (first passage)
muscle cells from antrum and fundus was reverse transcribed using 2 µg of total RNA. The
cDNA was amplified with specific primers for Rho kinase II. The sequences of specific primers
are listed in Table 1. Quantitative real-time polymerase chain reaction (qRT-PCR) was used to
measure RNA levels of Rho kinase II. For each cDNA sample, real-time PCR was conducted in
a 20 μl reaction volume containing Quantitect

TM

SYBRgreen PCR Mastermix. Real-time PCR

reactions were performed in triplicate. Each primer set generated only one PCR product (64 bp),
and the identity and integrity of these products were confirmed by electrophoresis in agarose gel
in the presence of ethidium bromide and sequencing of the individual bands. Standard curves for
each amplicon were generated from a dilution series of cDNA and results were quantified and
−ΔΔCT

reported using the 2

method based on GAPDH amplification. Relative quantification of a

target gene in relation to reference gene was calculated on the basis of delta delta CT values.
Results demonstrated that mRNA levels of Rho kinase II are higher in fundus compared to
antrum. Inset: Representative western blot results of Rho kinaseII expression. Cell lysates
containing equal amounts of total proteins were separated with SDS-PAGE and expression of
Rho kinase II was analyzed using selective antibody for Rho kinase II.

Membranes were

reblotted to measure β-actin. Protein bands visualized with enhanced chemiluminescence, images
were quantified and densitometric values were calculated after normalization to β-actin density.
Results are expressed as fold increase over the expression of Rho kinase II in antrum.
represent the means SEM of 3 separate experiments. **p<0.001 versus antrum.
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Values

Figure 17
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Figure 18. Stimulation of Rho kinase activity by ACh. One milliliter of cell suspension (2x
106 cells/ml) of freshly dispersed muscle cells from antrum and fundus was treated with ACh (0.1
µM) for 10 min in the presence or absence of Y27632 (1 µM), a selective inhibitor of Rho kinase.
The cells were homogenized in the lysis buffer and the protein content in the supernatants was
measured. Rho kinase II was immunoprecipitated from lysates containing equal amount of
protein and the activity was measured in immunoprecipitates using purified recombinant myelin
basic protein as substrate and [32P]ATP.

The amount of radioactivity absorbed onto

phosphocellulose disks reflecting kinase activity was by measured by liquid scintillation and the
results are expressed as counts per milligram protein per minute. ACh stimulated Rho kinase II
activity in antrum and fundus and the stimulation was higher in fundus compared to antrum.
Y27632 blocked stimulation of Rho kinase activity in both antrum and fundus. Values represent
the means SEM of 5-6 separate experiments. **p<0.001 significant increase in activity above
basal level induced by ACh; ##p<0.05 significant increase in activity in fundus versus increase in
antrum
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5.2

ZIPK expression and activity
Zipper interacting protein kinase (ZIPK) was also shown to inhibit MLCP activity via

phosphorylation of MYPT1 at Thr696. So, it is of interest to reveal any differential expression and
activity of this kinase in antrum versus fundus. Expression of ZIPK, by both qRT-PCR and
western blot, and stimulation of ZIPK activity in response to ACh (0.1µM) were determined in
muscle cells from antrum and fundus. ZIPK mRNA was expressed in both antrum and fundus,
and the expression was not significantly different between fundus and antrum (Figure 19). ZIPK
kinase protein expression was examined in the two regions of the stomach by western blot
analysis using selective antibody to ZIPK. Results confirmed the expression of ZIPK of expected
size (52 kDa) in the homogenates of smooth muscle cells from both antrum and fundus.
Comparing the densities of protein bands in the two regions revealed no significant difference of
ZIPK expression between fundus and antrum (figure 19).
ZIPK activity was measured by immunokinase assay using recombinant myelin basic
protein as substrate. Basal ZIPK activity was not significantly different in antrum (3106308
cpm/mg protein) and fundus (4107372 cpm/mg protein). Treatment of freshly dispersed muscle
cells with ACh (0.1 µM) significantly increased ZIPK activity in antrum (20511% increase;
6375438 cpm/mg protein above basal level, p<0.001, n=5) and fundus (4418% increase;
222571980 cpm/mg protein above basal level, p0.001, n=5) (Figure 20).

Consistent with the

greater expression and activation of Rho kinase in fundus, ACh-stimulated ZIPK activity was
significantly higher in fundus compared to antrum. ACh stimulated ZIPK activity was blocked by
pretreatment of cells with Y27632 (1 µM), a selective Rho kinase inhibitor, in antrum (845%
inhibition) and fundus (955% inhibition) (Figure 20). These results suggest that ZIPK is a
downstream target of Rho kinase.
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Figure 19. Expression of zipper interacting protein kinase. Total RNA isolated from cultured
(first passage) muscle cells from antrum and fundus was reverse transcribed using 2 µg of total
RNA. The cDNA was amplified with specific primers for ZIPK. The sequences of specific
primers are listed in Table 1. Quantitative real-time polymerase chain reaction (qRT-PCR) was
used to measure RNA levels of ZIPK. For each cDNA sample, real-time PCR was conducted in a
20 μl reaction volume containing Quantitect

TM

SYBRgreen PCR Mastermix. Real-time PCR

reactions were performed in triplicate. Each primer set generated only one PCR product (64 bp),
and the identity and integrity of these products were confirmed by electrophoresis in agarose gel
in the presence of ethidium bromide and sequencing of the individual bands. Standard curves for
each amplicon were generated from a dilution series of cDNA and results were quantified and
−ΔΔCT

reported using the 2

method based on GAPDH amplification. Relative quantification of a

target gene in relation to reference gene was calculated on the basis of delta delta CT values.
Results demonstrated that mRNA levels of ZIPK are not significantly different between fundus
and antrum.

Inset: Representative western blot results of ZIPK expression.

Cell lysates

containing equal amounts of total proteins were separated with SDS-PAGE and expression of
ZIPK was analyzed using selective antibody for ZIPK. Membranes were reblotted to measure βactin. Protein bands were visualized with enhanced chemiluminescence, images were quantified
and densitometric values were calculated after normalization to β-actin density. Results are
expressed as fold increase over the expression of ZIPK in antrum. Values represent the means
SEM of 3 separate experiments.
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Figure 20. Stimulation of ZIPK by ACh and sensitivity to the Rho kinase inhibitor, Y27632.
One milliliter of cell suspension (2x 106 cells/ml) of freshly dispersed muscle cells from antrum
and fundus was treated with ACh (0.1 µM) for 10 min in the presence or absence of Y27632 (1
µM), a selective inhibitor of Rho kinase. The cells were homogenized in the lysis buffer and the
protein content in the supernatants was measured. ZIPK was immunoprecipitated from lysates
containing equal amount of protein and the activity was measured in immunoprecipitates using
purified recombinant myelin basic protein as substrate and [32P]ATP.

The amount of

radioactivity absorbed onto phosphocellulose disks reflecting kinase activity was measured by
liquid scintillation and the results are expressed as counts per milligram protein per minute. ACh
stimulated ZIPK activity in antrum and fundus and the stimulation was higher in fundus
compared to antrum. Y27632 blocked stimulation of ZIPK activity in both antrum and fundus.
Values represent the means SEM of 5-6 separate experiments. **p<0.001 significant increase in
activity above basal level induced by ACh; ##p<0.05 significant increase in activity in fundus
versus increase in antrum
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5.3

Sustained contraction
To examine the involvement of Rho kinase/ZIPK pathway in the regulation of muscle

contraction, muscle cells from antrum and fundus were treated with different concentrations of
ACh and contractile response at 10 min was measured by scanning micrometry. Previous studies
in gastrointestinal smooth muscle have demonstrated that the contractile response at 10 min
reflects activation of Rho kinase- and PKC-dependent inhibition of MLCP. Treatment of cells
with ACh for 10 min caused contraction that was concentration-dependent with an EC50 of 1.1 
0.3 nM in antrum and 0.70.03 nM in fundus. The maximal response was significantly greater in
muscle cells from fundus (262 % decrease in cell length) compared to muscle cells from antrum
(182% decrease in cell length) (figure 21).
5.4

CPI-17 Expression
As described earlier, sustained MLC20 phosphorylation and muscle contraction are

mediated by inhibition of MLCP via Rho kinase/MTPT1 and PKC/CPI-17 pathways. Expression
of CPI-17, by both qRT-PCR and western blot was determined in muscle cells from antrum and
fundus. CPI-17 mRNA was expressed in antrum and fundus and the expression was nearly 4-fold
higher in fundus compared to antrum (figure 22). CPI-17 protein expression was examined in the
two regions of the stomach by western blot using selective antibody to CPI-17. Results confirmed
the expression of CPI-17 of expected size (17 kDa) in the homogenates of smooth muscle cells
from both antrum and fundus (Figure 22). Comparing the densities of protein bands in the two
regions revealed 4-fold (p<0.05) higher expression of CPI-17 in fundus compared to antrum and
this is consistent with higher expression of CPI-17 mRNA in fundus compared to antrum.
5.5

PMA-stimulated PKC activity and smooth muscle contraction
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Since contractile agonists stimulate both Rho kinase and PKC activities, the singular
contribution of PKC/CPI-17 pathway in mediating MLCP inhibition and sustained contraction
was examined using phorbol 12-myristate 13-acetate (PMA), a selective activator of PKC.
Treatment of cells with PMA caused contraction that was concentration-dependent with an EC50
of 355 nM in antrum and 32 nM in fundus.

The maximal contractile response was

significantly greater in muscle cells from fundus (292% decrease in cell length) compared to
muscle cells from antrum (173% decrease in cell length) (figure 23A). However, stimulation of
PKC activity in response to PMA was similar in antrum (3245504 cpm/mg protein above the
basal level of 523102 cpm/mg protein) and fundus (3612302 cpm/mg protein above the basal
level 675129 cpm/mg protein) (Figure 23B). These results suggest that greater contraction in
fundus is not due difference in the PKC activity, but probably due to higher expression of CPI-17
and CPI-17-mediated inhibition of MLCP activity.
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Figure 21. ACh-induced sustained muscle contraction. Contraction of dispersed muscle cells
from antrum and fundus in response to different concentrations of ACh was measured by
scanning micrometry. Cells were treated with ACh (0.1 µM) for 10 min and cntraction was
expressed as percent decrease in cell length from control cell length: control length of muscle
cells from antrum 953 µm; control length of muscle cells from fundus 1025 µm. ACh caused
contraction that was concentration-dependent in both antrum and fundus and the contraction was
greater in fundus compared to antrum. The maximal response to 0.1 µM ACh was significantly
greater in muscle cells from fundus (262 % decrease in cell length) compared to muscle cells
from antrum (182% decrease in cell length). Values represent the means SEM of 4 separate
experiments. *p<0.05 significant increase in contraction in fundus versus contraction in antrum.
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Figure 22. Expression of CPI-17.

Total RNA isolated from cultured (first passage) muscle

cells from antrum and fundus was reverse transcribed using 2 µg of total RNA. The cDNA was
amplified with specific primers for CPI-17. The sequences of specific primers are listed in Table
1. Quantitative real-time polymerase chain reaction (qRT-PCR) was used to measure RNA levels
of CPI-17. For each cDNA sample, real-time PCR was conducted in a 20 μl reaction volume
TM

containing Quantitect

SYBRgreen PCR Mastermix. Real-time PCR reactions were performed

in triplicate. Each primer set generated only one PCR product (116 bp), and the identity and
integrity of these products were confirmed by electrophoresis in agarose gel in the presence of
ethidium bromide and sequencing of the individual bands.

Standard curves for each amplicon

were generated from a dilution series of cDNA and results were quantified and reported using the
−ΔΔCT

2

method based on GAPDH amplification. Relative quantification of a target gene in

relation to reference gene was calculated on the basis of delta delta CT values.

Results

demonstrated that mRNA levels of CPI-17 are significantly higher in fundus compared to antrum.
Inset: Representative western blot results of CPI-17 expression. Cell lysates containing equal
amounts of total proteins were separated with SDS-PAGE and expression of CPI-17 was
analyzed using selective antibody for CPI-17. Membranes were reblotted to measure β-actin.
Protein bands visualized with enhanced chemiluminescence, images were quantified and
densitometric values were calculated after normalization to β-actin density. Results are expressed
as fold increase over the expression of CPI-17 in antrum. Values represent the means SEM of 3
separate experiments. **p<0.05 versus antrum.
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Figure 23. PMA-induced sustained muscle contraction and PKC activity. A. Contraction of
dispersed muscle cells from antrum and fundus in response to different concentrations of phorbol
12-myristate 13-acetate (PMA) was measured by scanning micrometry.

Contraction was

expressed as percent decrease in cell length from control cell length: control length of muscle
cells from antrum 953 µm; control length of muscle cells from fundus 1025 µm. PMA caused
contraction that was concentration-dependent in both antrum and fundus and the contraction was
greater in fundus compared to antrum. The maximal response to 1 µM PMA was significantly
greater in muscle cells from fundus (292 % decrease in cell length) compared to muscle cells
from antrum (172% decrease in cell length). Values represent the means SEM of 4 separate
experiments. *p<0.05 significant increase in contraction in fundus versus contraction in antrum.
B. One milliliter of cell suspension (2x 106 cells/ml) of freshly dispersed muscle cells from
antrum and fundus was treated with PMA (1 µM) for 10 min. The cells were homogenized in the
lysis buffer and the protein content in the supernatants was measured.

PKC was

immunoprecipitated from lysates containing equal amount of protein with a PKC antibody and
the activity was measured in immunoprecipitates using purified recombinant myelin basic protein
as substrate and [32P]ATP. The amount of radioactivity absorbed onto phosphocellulose disks
reflecting kinase activity was by measured by liquid scintillation and the results are expressed as
counts per milligram protein per minute above basal levels of 523102 cpm/mg protein in antrum
and 675129 cpm/mg protein in fundus. PMA stimulated PKC activity was similar in antrum
and fundus. Values represent the means SEM of 4 separate experiments.
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CHAPTER 6
DIFFERENTIAL REGULATION OF MLCP ACTIVITY AND MUSCLE RELAXATION
IN ANTRUM AND FUNDUS

In gastrointestinal smooth muscle two endogenous proteins regulate MLCP activity: a 17
kDa inhibitor (CPI-17) and a 17 kDa activator, telokin, also known as kinase-related protein.
Telokin is a smooth muscle specific protein and is identical to the C-terminus of MLCK
downstream from the kinase and calmodulin binding domains. We postulated that the higher
expression of telokin, and activation MLCP leading to MLC20 dephosphorylation could
contribute to rapid relaxation and phasic phenotype of antrum.
6.1

Telokin Expression
Expression of telokin by both qRT-PCR and western blot was determined in muscle cells

from antrum and fundus. Telokin mRNA was expressed in both antrum and fundus and the
expression was 6-fold higher in antrum compared to fundus (figure 24).

Telokin protein

expression was examined in the two regions of the stomach by western blot using selective
antibody to telokin. Results confirmed the expression of telokin of expected size (17 kDa) in the
homogenates of smooth muscle cells from both antrum and fundus (Figure 24). Comparing the
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densities of protein bands in the two regions revealed 5-fold higher expression of telokin in
antrum compared to fundus and this is consistent with higher expression of telokin mRNA in
antrum compared to fundus.
6.2

8-Br-cGMP-stimulated PKG activity and smooth muscle relaxation
Since the relaxant effect of cGMP/PKG pathway on agonist-mediated (e.g., ACh)

contraction involves both inhibition of intracellular Ca2+ and activation of MLCP, relaxation was
measured as inhibition of maximal contraction in response to 0.5 µM Ca2+.

Under these

experimental conditions, the effect of cGMP/PKG on Ca2+ is precluded and reflects stimulation
of MLCP activity, probably via telokin. Since termination of cGMP/PKG signaling is different in
antrum and fundus and depends on the expression of PDE5 (see next chapter), 8-Br-cGMP, a
non-hydrolyzable analog of cGMP, was used to induce muscle relaxation.

Treatment of

permeabilized muscle cells with 0.5 µM Ca2+ caused contraction that was similar in muscle cells
from antrum (243% decrease in cell length from a basal cell length of 853 µm) and fundus
(262% decrease in cell length from a basal cell length of 924 µm). Pretreatment of cells with
8-Br-cGMP (1mM) caused relaxation (i.e., inhibition of contraction) that was concentrationdependent (EC50: antrum, 83 µM; fundus, 124). Relaxation was significantly higher in antrum
compared to fundus at all concentrations of 8-Br-cGMP. The maximal response was significantly
greater in muscle cells from antrum (764% relaxation) compared to muscle cells from fundus
(473% relaxation) (figure 25 A). However, stimulation of PKG activity in response to 8-BrcGMP was similar in antrum (-GMP/+cGMP activity ratio, 2.40.4) and fundus (-cGMP/+cGMP
activity ratio, 2.20.3) suggesting that lower relaxation in fundus was not due to cGMP
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degradation via PDE5 or efflux via MRP5, and possibly reflects lower expression of telokin
(figure 25 B).
6.3

Telokin-dependent stimulation of MLCP activity
Previous studies have demonstrated that PKG-mediated phosphorylation of telokin at

Ser13 greatly augments the ability of telokin to stimulate MLCP activity. We tested the role of
telokin in cGMP/PKG-mediated relaxation by overexpressing cultured muscle cells with wild
type or phosphorylation-deficient telokin (S13A). Relaxation in response to 8-Br-cGMP was
measured as decrease in Ca2+ (0.5 µM)-induced MLC20 phosphorylation.

Treatment of cells,

containing either wild type or telokin S13A mutant with 0.5 µM Ca2+ for 1 minute significantly
augmented phosphorylation of MLC20 at Ser19. The extent of phosphorylation was similar in
both antrum and fundus and consistent with similar levels of contraction as described above.
Pretreatment of cells with 8-Br-cGMP inhibited MLC20 phosphorylation in both fundus (485%
inhibition) and antrum (786% inhibition) suggesting dephosphorylation of MLC20 due to
activation of MLCP. The inhibitory effect 8-Br-cGMP was significantly (p<0.05, n=4) higher in
antrum compared to fundus, and reflects higher expression of telokin in antrum compared to
fundus (figures 26 and 27).
The inhibitory effect of 8-Br-cGMP on MLC20 phosphorylation was significantly
attenuated in cells expressing telokin S13A suggesting that the effect of 8-Br-cGMP was due to
augmentation of MLCP activity via phosphorylation of telokin at Ser13. Importantly, in the
presence of telokin (S13A), the inhibitory effect of 8-Br-cGMP was not significantly different
between antrum and fundus (figures 26 and 27). These results provide conclusive evidence for
the involvement of telokin in the activation of MLCP and MLC20 dephosphorylaiton. Higher
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expressions of telokin and MLCP activity in antrum also correlate with the phasic phenotype of
this muscle, where rapid contractions and relaxations are needed for optimal organ function.
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Figure 24. Expression of telokin. Total RNA isolated from cultured (first passage) muscle cells
from antrum and fundus was reverse transcribed using 2 µg of total RNA. The cDNA was
amplified with specific primers for telokin. The sequences of specific primers are listed in Table
1. Quantitative real-time polymerase chain reaction (qRT-PCR) was used measure RNA levels of
telokin. For each cDNA sample, real-time PCR was conducted in a 20 μl reaction volume
TM

containing Quantitect

SYBRgreen PCR Mastermix. Real-time PCR reactions were performed

in triplicate. Each primer set generated only one PCR product (69 bp), and the identity and
integrity of these products were confirmed by electrophoresis in agarose gel in the presence of
ethidium bromide and sequencing of the individual bands.

Standard curves for each amplicon

were generated from a dilution series of cDNA and results were quantified and reported using the
−ΔΔCT

2

method based on GAPDH amplification. Relative quantification of a target gene in

relation to reference gene was calculated on the basis of delta delta CT values.

Results

demonstrated that mRNA levels of telokin are significantly higher in antrum compared to fundus
Inset: Representative western blot results of telokin expression. Cell lysates containing equal
amounts of total proteins were separated with SDS-PAGE and expression of telokin was analyzed
using selective antibody for telokin. Membranes were reblotted to measure β-actin. Protein bands
were visualized with enhanced chemiluminescence, images were quantified and densitometric
values were calculated after normalization to β-actin density. Results are expressed as fold
increase over the expression of telokin in fundus.
separate experiments. **p<0.001 versus fundus.
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Values represent the means SEM of 3

Figure 24
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Figure 25. 8-Br-cGMP-induced muscle relaxation and PKG activity. A. Relaxation of
dispersed muscle cells from antrum and fundus in response to different concentrations of 8-BrcGMP was measured by scanning micrometry as decrease in Ca2+-induced contraction.
Contraction in response to 0.5 µM Ca2+ was measured in permeabilized muscle cells.
Contraction was similar in muscle cells from antrum (243% decrease in cell length from a basal
cell length of 853 µm) and fundus (262% decrease in cell length from a basal cell length of
924 µm). 8-Br-cGMP caused relaxation that was concentration-dependent in both antrum and
fundus and the relaxation was greater in antrum compared to fundus. The maximal response to 1
mM 8-Br-cGMP that was significantly greater in antrum (764% relaxation) compared to muscle
cells from fundus (473% relaxation).

Values represent the means SEM of 4 separate

experiments. *p<0.05 significant increase in relaxation in antrum versus relaxation in fundus. B.
One milliliter of cell suspension (2 x 106 cells/ml) of freshly dispersed muscle cells from antrum
and fundus was treated with 8-Br-cGMP (1 mM) for 10 min. The cells were homogenized in the
lysis buffer and the protein content in the supernatants was measured.

PKG activity was

measured in the presence or absence of cGMP using a specific substrate RKRSRAE and
[32P]ATP, and the results are expressed as the ratio of activity in the absence or presence of
cGMP. 8-Br-cGMP-stimulated PKG activity was similar in antrum and fundus. Values represent
the means SEM of 3 separate experiments.

110

Figure 25

111

Figure 26. Inhibition of Ca2+-induced MLC20 phosphorylation by 8-Br-cGMP and the
effect of telokin in muscle cells from fundus.

Cultured muscle cells from fundus

overexpressing wild type telokin or phosphorylation-deficient telokin (telokin S13A) were
permeabilized, pretreated with 8-Br-cGMP (1 mM) and then treated with 0.5 µM Ca2+. MLC20
phosphorylation was measured in MLC20 imunoprecipitates using antibody specific for phosphoSer19 MLC20 by immunoblot analysis. Densitometric values were calculated after normalization
to MLC20 density and the results expressed as percent of control density. Ca2+-induced MLC20
phosphorylation was significantly inhibited in cells expressing wild type telokin, but not in cells
expressing telokin S13A.

Values represent the means SEM of 3 separate experiments.

**p<0.001 significant increase in MLC20 phosphorylation by Ca2+, ##p<0.05 significant
inhibition of Ca2+-induced MLC20 phosphorylation by 8-Br-cGMP.
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Figure 27. Inhibition of Ca2+-induced MLC20 phosphorylation by 8-Br-cGMP and the
effect of telokin in muscle cells from antrum.

Cultures muscle cells from antrum

overexpressing wild type telokin or phosphorylation-deficient telokin (telokin S13A) were
permeabilized, pretreated with 8-Br-cGMP (1 mM) and then treated with 0.5 µM Ca2+. MLC20
phosphorylation was measured in MLC20 imunoprecipitates using antibody specific for phosphoSer19 MLC20 by immunoblot analysis. Densitometric values were calculated after normalization
to MLC20 density and the results expressed as percent of control density. Ca2+-induced MLC20
phosphorylation was significantly inhibited in cells expressing wild type telokin, but not in cells
expressing telokin S13A. The inhibition of MLC20 phosphorylation was significantly greater in
antrum (786% inhibition) compared to fundus (485% inhibition) (compare Figs 26 and 27).
Values represent the means SEM of 3 separate experiments. **p<0.001 significant increase in
MLC20 phosphorylation by Ca2+, ## p<0.05 significant inhibition of Ca2+-induced MLC20
phosphorylation by 8-Br-cGMP.
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CHAPTER 7
REGULATION OF CYCLIC GMP LEVELS AND MUSCLE RELAXATION IN
ANTRUM AND FUNDUS

In the gastrointestinal smooth muscle, the main inhibitory transmitters vasoactive
intestinal peptide (VIP) and nitric oxide (NO) induce relaxation through the generation of cAMP
and cGMP, and activation of cAMP-dependent protein kinase (PKA) and cGMP-dependent
protein kinase (PKG). Although generation of both nucleotides and activation of both kinases are
the physiological norm, studies in mice lacking sGC or PKGI suggest an important role for
sGC/cGMP/PKG pathway in smooth muscle relaxation

106-108

. The strength and duration of

cGMP signaling is regulated by its degradation into inactive 5′GMP via cGMP-specific PDE5,
and efflux via ATP-dependent transporter, MRP5. We postulated that the termination of cGMP
effect by both PDE5 and MRP5 in tonic muscle could contribute to rapid return to tonic
contractile phenotype following a relaxation.
7.1

PDE5 Expression and Activity
Expression of PDE5, by both qRT-PCR and western blot, and stimulation of PDE5

activity in response to NO-donor, s-nitrosoglutathione (GSNO), were determined in muscle cells
from antrum and fundus. PDE5 mRNA was expressed in both antrum and fundus and the
expression was 2-fold higher in fundus compared to antrum (figure 28). PDE5 protein expression
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was examined in the two regions of the stomach by western blot using selective antibody to
PDE5A, the smooth muscle predominant isoform109. Results confirmed the expression of PDE5
of expected size (100 kDa) in the homogenates of smooth muscle cells from both antrum and
fundus (figure 28). Comparing the densities of protein bands in the two regions revealed a 3-fold
higher expression of PDE5 in fundus compared to antrum and this is consistent with the higher
expression of PDE5 mRNA in fundus compared to antrum (Figure 28).
Basal

and

GSNO-stimulated

PDE5

activity

was

measured

by

ion-exchange

chromatography using [3H]cGMP as substrate. Although, the expression levels are different,
basal PDE5 activity was not significantly different in antrum (23856 cpm/mg protein) and
fundus (28545 cpm/mg protein). Treatment of dispersed muscle cells with GSNO increased
PDE5 activity in a concentration-dependent fashion in antrum and fundus. Stimulation of PDE5
activity was significantly higher at concentrations above 10 nM of GSNO in fundus compared to
antrum (Figure 29A). The maximal stimulation was also significantly higher (p<0.05, n=6) in
fundus (3212 245 cpm/mg protein) compared to antrum (2189310 cpm/mg protein).
Further evidence for higher PDE5 activity in fundus was obtained by measurements of
cGMP levels in response to GSNO. GSNO increased cGMP levels in muscle cells from both
regions in a concentration-dependent fashion. Basal levels of cGMP are similar in antrum
(0.280.04 pmol/mg protein) and fundus (0.210.03pmol/mg protein).

However, GSNO-

stimulated cGMP levels were significantly lower in fundus compared to antrum. The maximal
stimulation was also significantly lower in fundus (573% increase above basal levels) compared
to antrum (764% increase above basal levels of cGMP) (Figure 29 B). The results are consistent
with the higher PDE5 expression and activity in fundus compared to antrum.
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Figure 28. Expression of PDE5A. Total RNA isolated from cultured (first passage) muscle
cells from antrum and fundus was reverse transcribed using 2 µg of total RNA. The cDNA was
amplified with specific primers for PDE5A. The sequences of specific primers are listed in Table
1. Quantitative real-time polymerase chain reaction (qRT-PCR) was used to measure RNA levels
of PDE5A. For each cDNA sample, real-time PCR was conducted in a 20 μl reaction volume
TM

containing Quantitect

SYBRgreen PCR Mastermix. Real-time PCR reactions were performed

in triplicate. Each primer set generated only one PCR product (65bp), and the identity and
integrity of these products were confirmed by electrophoresis in agarose gel in the presence of
ethidium bromide and sequencing of the individual bands.

Standard curves for each amplicon

were generated from a dilution series of cDNA and results were quantified and reported using the
−ΔΔCT

2

method based on GAPDH amplification. Relative quantification of a target gene in

relation to reference gene was calculated on the basis of delta delta CT values.

Results

demonstrated that mRNA levels of PDE5A are significantly higher in fundus compared to
antrum. Inset: Representative western blot results of PDE5A expression. Cell lysates containing
equal amounts of total proteins were separated with SDS-PAGE and expression of PDE5A was
analyzed using selective antibody for PDE5A. Membranes were reblotted to measure β-actin.
Protein bands were visualized with enhanced chemiluminescence, images were quantified and
densitometric values were calculated after normalization to β-actin density. Results are expressed
as fold increase over the expression of PDE5 in antrum. Values represent the means SEM of 3
separate experiments. **p<0.001 versus antrum.
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Figure 28
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Figure 29. Stimulation of PDE5 activity and cGMP formation by GSNO. A. One milliliter
of cell suspension (2x 106 cells/ml) of freshly dispersed muscle cells from antrum and fundus was
treated with different concentrations of s-nitrosoglutathione (GSNO), an NO-donor, for 60 s. The
cells were homogenized in the lysis buffer and the protein content in the supernatants was
measured. PDE5 was immunoprecipitated from lysates containing equal amount of protein and
the activity was measured in immunoprecipitates by liquid chromatography using [3H]cGMP as
substrate. The amount of radioactivity in the elutes was measured by liquid scintillation and the
results are expressed as counts per milligram protein per minute. GSNO stimulated PDE5
activity in a concentration-dependent manner and the stimulation was significantly higher in
fundus compared to antrum. Values represent the means SEM of 5-6 separate experiments.
*p<0.05 significant increase in PDE5 activity in fundus compared to antrum. B. One milliliter of
cell suspension (2 x 106 cells/ml) of freshly dispersed muscle cells from antrum and fundus was
treated with different concentrations of s-nitrosoglutathione (GSNO) for 60 s and the reaction was
terminated with 10% trichloroacetic acid. Cyclic GMP was measured by radioimmuno assay
using [125I]cGMP and the results were expressed as percent increase above basal levels (basal
levels in antrum 0.280.04 pmol/mg protein; basal level in fundus 0.210.03pmol/mg protein).
GSNO stimulated cGMP levels in a concentration-dependent manner and the stimulation was
significantly lower in fundus compared to antrum. Values represent the means SEM of 5
separate experiments. *p<0.05 significant lower cGMP levels in fundus compared to antrum.
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7.2

MRP5 Expression
Another important mechanism in keeping intracellular cyclic nucleotides within narrow

limits is their efflux into the extracellular space via ATP-dependent multidrug resistant proteins
(MRPs). MRP5 has been identified as a cGMP export pump in the heart and vasculature, but its
expression and function in gastrointestinal smooth muscle are not known. Specific primers for
MRP5 were designed based on corresponding conserved sequences in human, rat, and mouse
cDNAs (Table 1). MRP5 was detected by RT-PCR using RNA extracted from cultures of whole
gastric smooth muscle cells in first passage. Cloning and sequence analysis of the RT-PCR
product of MRP5 in the stomach was 98% similar to the corresponding amino acid sequences of
human. Expression of MRP5 mRNA was higher in fundus compared to antrum (Figure 30).
MRP5 protein expression was examined in the two regions of the stomach by western blot
using selective antibody to MRP5. Results confirmed the expression of MRP5 of expected size
(185 kDa) in the homogenates of smooth muscle cells from both antrum and fundus. Comparing
the densities of protein bands in the two regions revealed a 5-fold higher expression of MRP5 in
fundus compared to antrum (Figure 30).
7.3

cGMP efflux
The function of MRP5 was analyzed by measuring intra- and extracellular cGMP levels in

response to GSNO. To exclude the involvement of PDE5 and examine the singular contribution
of MRP5 in the regulation of intracellular cGMP levels, experiments were done in the presence of
a non-selective PDE inhibitor, IBMX (100 µM). Under these experimental conditions, changes
in intracellular cGMP reflect efflux of cGMP, probably via MRP5. GSNO caused an increase in
both intra- (14610% increase above basal level of 0.420.05 pmol/mg protein) and extracellular
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(655% increase above basal level of 0.160.03 pmol/mg protein) cGMP levels in antrum, and
the increase in intracellular cGMP was greater compared to extracellular cGMP levels. GSNO
also caused an increase in both intra- (889 above basal level of 0.380.04 pmol/mg protein) and
extracellular (17615% increase above basal level of 0.180.03 pmol/mg protein) cGMP levels
in fundus, and the increase in extracellular cGMP was greater compared to intracellular cGMP
levels (Figure 31). Moreover, GSNO-induced cGMP efflux was blocked in cultured muscle cells
tranfected with MRP5 siRNA from both antrum and fundus (figure 32) but not in muscle cells
tranfected with control siRNA (figure33). The results are consistent with the higher expression of
cGMP-specific MRP5 in fundus compared to antrum and also consistent with the tonic phenotype
of fundus muscle where rapid restoration of contractile function is required for optimal function.
7.4

NO-induced smooth muscle relaxation
To examine the role of PDE5 and MRP5 pathways in the regulation of muscle function,

relaxation of muscle cells from antrum and fundus was measured by scanning micrometry.
Muscle relaxation was measured as inhibition of ACh-induced contraction in response to GSNO
as described previously. GSNO-induced muscle relaxation was concentration-dependent in both
antrum and fundus (Figure 34). Relaxation was significantly lower in fundus compared to antrum
and the maximal response was 733% in antrum and 584% in fundus (Figure 34). The results
are consistent with the higher PDE5 and MRP5 functions resulting in lower intracellular cGMP
levels in muscle cells from fundus compared to cells from antrum.
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Figure 30. Expression of MRP5. A. Total RNA isolated from cultured (first passage) muscle
cells from antrum and fundus was reverse transcribed using 2 µg of total RNA. The cDNA was
amplified with specific primers for MRP5. The sequences of specific primers are listed in Table
1. The primer set generated only one PCR product (151bp), and the identity and integrity of these
products were confirmed by electrophoresis in agarose gel in the presence of ethidium bromide
and sequencing of the individual band.
higher in fundus compared to antrum.

Results demonstrated that mRNA levels of MRP5 are
B. Representative western blot results of MRP5

expression. Cell lysates containing equal amounts of total proteins were separated with SDSPAGE and expression of MRP5 was analyzed using selective antibody for MRP5. Membranes
were reblotted to measure β-actin. Protein bands were visualized with enhanced
chemiluminescence, images were quantified and densitometric values were calculated after
normalization to β-actin density. Densitometric values showed that MRP5 expressin was 4-fold
higher in fundus compared to antrum.

Values represent the means SEM of 3 separate

experiments. **p<0.001 versus antrum.
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Figure 30

β
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Figure 31. Stimulation of cGMP efflux by GSNO. One milliliter of cell suspension (2 x 106
cells/ml) of freshly dispersed muscle cells from antrum and fundus was treated with GSNO for 10
min in the presence of non-specific PDE inhibitor, 100 µM isobutylmethyl xanthine (IBMX).
Under these experimental conditions, the effect of PDE5 on cGMP degradation was precluded.
Cyclic GMP was measured by radioimmuno assay using [125I]cGMP in the cell pellet and
supernatant to reflect intracellular and extracellular cGMP levels, respectively.

The results are

expressed as percent increase above basal level (antrum: basal intracellular 0.420.05 pmol/mg
protein; basal extracellular 0.160.03 pmol/mg protein; fundus: basal intracellular 0.380.04
pmol/mg protein; basal extracellular 0.180.03 pmol/mg protein). GSNO stimulated both intraand extracellular cGMP levels in antrum and fundus. The increase in intracellular levels was
higher in antrum compared to extracelluar levels. In contrast, increase in extracellular levels was
higher in fundus compared to intracelluar levels. Values represent the means SEM of 5 separate
experiments.

**p<0.05 significant increase in cGMP levels by GSNO above basal levels;

##p<0.05 significant increase in extracellular cGMP in fundus compared to antrum.
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Figure 32. cGMP efflux in cells transfecrted with MRP5 siRNA. Cultures muscle cells
transfected with MRP5 siRNA were treated with GSNO for 10 min in the presence of nonspecific PDE inhibitor, 100 µM isobutylmethyl xanthine (IBMX). Cyclic cGMP was measured
by radioimmuno assay using [125I]cGMP in the cell pellet and supernatant to reflect intracellular
and extracellular cGMP levels, respectively. The results are expressed as percent increase above
basal level (antrum: basal intracellular 0.380.04 pmol/mg protein; basal extracellular 0.13 0.02
pmol/mg protein; fundus: basal intracellular 0.35 0.04 pmol/mg protein; basal extracellular
0.160.02 pmol/mg protein). GSNO-stimulated extracellular cGMP levels were abolished in
cells transfected with MRP5 siRNA in antrum and fundus. Values represent the means SEM of
5 separate experiments. **p<0.001 significant increase in cGMP levels by GSNO above basal
levels. Left panel: MRP5 expression in cells transfected with control siRNA or MRP5siRNA
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Figure 33. cGMP efflux by in cells transfecrted with control siRNA. Cultures muscle cells
transfected with control siRNA were treated with GSNO for 10 min in the presence of nonspecific PDE inhibitor, 100 µM isobutylmethyl xanthine (IBMX). Cyclic cGMP was measured
by radioimmuno assay using [125I]cGMP in the cell pellet and supernatant to reflect intracellular
and extracellular cGMP levels, respectively. The results are expressed as percent increase above
basal level (antrum: basal intracellular 0.34 0.03 pmol/mg protein; basal extracellular 0.11 0.01
pmol/mg protein; fundus: basal intracellular 0.28 0.02 pmol/mg protein; basal extracellular
0.140.02 pmol/mg protein). GSNO stimulated both intra- and extracellular cGMP levels in
antrum and fundus. The increase in intracellular levels was higher in antrum compared to
extracelluar levels. In contrast, increase in extracellular levels was higher in fundus compared to
intracelluar levels. Values represent the means SEM of 5 separate experiments. *p<0.05
significant increase in cGMP levels by GSNO above basal levels; ##p<0.05 significant increase
in extracellular cGMP in fundus compared to antrum.
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Figure 33
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Figure 34. GSNO-induced muscle relaxation.

Relaxation of dispersed muscle cells from

antrum and fundus in response to different concentrations of s-nitrosoglutathione (GSNO) was
measured by scanning micrometry as decrease in ACh-induced contraction. Contraction was
measured in response to maximal concentrations of ACh (0.1 m) at 30 s as decrease in muscle
control cell length (antrum: control cell length 983 m; fundus: control cell length 914 m).
Contraction was similar in muscle cells from antrum (283% decrease) and fundus (292%
decrease). GSNO caused relaxation that was concentration-dependent in both antrum and fundus
and the relaxation was greater in antrum compared to fundus. The maximal response to 10 M
GSNO was significantly greater in antrum (733% relaxation) compared to muscle cells from
fundus (584% relaxation).

Values represent the means SEM of 4 separate experiments.

*p<0.05 significant increase in relaxation in antrum versus relaxation in fundus.
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Figure 34
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CHAPTER 8
DISCUSSION

Smooth muscle cells are the fundamental structural and functional units of the gastrointestinal
system and exhibit distinct contractile phenotypes. The underlying features of phasic muscles (e.g.,
distal stomach and intestine) are the ability to generate rhythmic contractions and relaxations, while
tonic muscles (e.g., sphincters and proximal stomach) have sustained tone and relax transiently in
response to relaxant transmitters.

Contractile agonists increase MLC20 phosphorylation by

Ca2+/CaM-dependent stimulation of MLCK and RhoA-dependent inhibition of MLCP activity.
Relaxant agonists decrease MLC20 phosphorylation either by decreasing Ca2+ levels or increasing
MLCP activity via PKA and PKG-dependent pathways. Although MLC20 phosphorylation is a
prerequisite of contraction in both muscle types, the biochemical basis of phasic and tonic phenotypes
of smooth muscle is not clear and is the major question of inquiry in the present study. The objective
of this project is to determine whether the expression of contractile protein isoforms, the regulation of
Ca2+/calmodulin-dependent MLCK and Rho kinase/ZIPK-dependent MLCP activity, and the
termination of cGMP signaling are different in phasic and tonic smooth muscle. Using biochemical,
molecular and functional approaches, and antrum (distal stomach) and fundus (proximal stomach) of
rabbit stomach as models of phasic and tonic smooth muscle, respectively, the present study
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characterized the differences in the signaling pathways that regulate MLCK and MLCP activities and
cGMP levels. Expression of contractile proteins is tissue specific with higher levels of caldesmon,
calponin, tropomyosin and smoothelin A expression in antrum compared to fundus. In muscle cells
from antrum MLCK activity is under feedback negative control by higher expression and activation
of CaMKKβ/AMPK pathway, and MLCP is positively regulated by higher expression of telokin, an
endogenous MLCP activator. In muscle cells from fundus, in contrast, MLCP activity is suppressed
by higher expression and activation of Rho kinase/ZIPK/MYPT1 and PKC/CPI-17 pathways, and
cGMP/PKG pathway is attenuated by rapid degradation and efflux of cGMP via higher expression
PDE5 and MRP5, respectively (figure 33). These differences in the biochemical pathways highly
correlate with the functional phasic phenotype of antrum and tonic phenotype of fundus.

8.1

Differences in the contractile protein content and isoforms and their associated

proteins

It is hypothesized that differences in the mechanical behavior between tonic and phasic
smooth muscles could be due to differences in the contractile proteins themselves; actin, myosin
and their associated proteins such as caldesmon and calponin. Previous studies110,111 have
demonstrated that the tonic muscle myosin has a greater affinity for MgADP at low
phosphorylation levels than the phasic myosin, a property that aids in maintaining the developed
force in tonic muscles. In this study, we investigated the content and isoform distribution of the
main contractile proteins; actin and myosin, and the thin filament associated proteins;
tropomyosin, caldesom, calponin, and smoothelin in smooth muscles of the antrum and fundus.
The results showed that the expression of contractile proteins is tissue specific with higher levels
of caldesmon, calponin, tropomyosin and smoothelin A expression in antrum compared to
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fundus. These results are consistent with the results previous studies using different models of
phasic and tonic tissues in different species6,112,113.

8.1.1

Myosin isoforms
Myosin molecule is a hexamer with 2 subunits of smooth muscle-specific myosin heavy

chain (MHC), a pair of 17 kDa MLC and a pair 20 kDa MLC (MLC20). Alternative RNA
processing of a single gene generates four isoforms of MHC.

Alternate splicing of a 21-

neoclutide exon at the 5‟ end of the gene results in the presence (SMB isoform) or absence (SMA
isoform) of a seven-amino acid insert at the globular head region of the MHC molecule114. In
addition, alternate splicing of a 39-neoclutide exon in the non-helical portion of the 3‟ end of the
gene coding for 9 unique amino acids at the COOH terminus and an in-frame stop codon results
in a molecule that is 34 amino acids shorter (SM2) than the alternately spliced isoform (SM1)115.
It has been suggested that differential expression of myosin heavy chain isoforms may
influence smooth muscle contractility116, Chi et al., for example, have found that ablation of
smooth muscle myosin heavy chain SM2 increases smooth muscle contraction117. Others have
found a positive correlation between SM1 myosin content and maximal velocity of muscle
shortening (Vmax) in rat uterine smooth muscle116. In the present study, we could detect SM1 and
SM2 isoforms only in antrum, and that SM1 expression was greater than SM2.
Our results are consistent with this proposed function of these MHC isoforms in smooth
muscle. In antrum, higher SM1 expression might be pertinent with the rapid crossbridge cycling
and as a result smooth muscle shortening and contraction that is needed in this region of the
stomach which is characterized by rapid contraction and relaxation cycles. In addition, greater
SM2 expression in this distal part of the stomach might be of importance in preventing the
development of any basal tone, and thus leading to rapid fade of the stimulated contraction in the
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phasic smooth muscles of the antrum. Eddinger et al.,75, on the other hand, reported
approximately equal amounts of both SM1 and SM2 MHC isoforms in all regions of the rabbit
stomach. However, these measurements were made on tissue pieces taken from different
locations along the greater curvature of the stomach and this expression pattern might differ at the
cellular level.
Regarding MHC isoforms with (SMB) and without (SMA) the seven-amino acid insert at
the globular head region of the MHC molecule, Kelley et al.
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showed that the phasic chicken

gizzard, but not the tonic chicken aortic smooth muscle, contains myosin with the seven-amino
acid insert and showed that the presence of SMB isoform correlates with a higher velocity of
movement of actin filaments over myosin heads in the in vitro motility assay and a higher actinactivated myosin ATPase activity. Moreover, DiSanto et al.,
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howed that the inserted myosin

mRNA level increases in more distal muscular arteries that show phasic contractions compared to
aorta which primarily possesses tonic activity.
By measuring mRNA expression levels in cultured gastric smooth muscle cells, we
demonstrated that antrum contains greater SMB but lower SMA mRNA contents than fundus.
This is consistent with the previous reports and with the proposed functional role of these
isoforms with actomyosin ATPase activity and maximum shortening velocity, which are greater
in phasic smooth muscles than in tonic ones. Further work is needed to examine the correlation
between protein expression of each of these different isoforms and RNA expression pattern.
It is important to mention that other myosin II isoforms might add a complexity to the
above mentioned differences between phasic and tonic smooth muscles. For example, it is known
that non-muscle myosin (NMII A, B, and C) interacts with actin and converts the chemical
energy from ATP hydrolysis to force120. The expression of non-muscle myosin isoforms, NMIIA
and NMIIB, has been well documented to be different between phasic and tonic smooth muscle.
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It has been reported that NMIIA isoform is predominating in the phasic mouse bladder muscle,
while NMIIB is the major isoform in the tonic aorta121. Whether these non-muscle myosins are
regionally distributed in the GI tract or have a functional contribution to muscle contractility is
not known yet.
8.1.2

Actin isoforms
Of the thin filaments, actin stands as the major constituent and plays an important role,

with myosin, in crossbridge formation. Three major actin isoforms are expressed in smooth
muscle; α, β, and γ. The β -isoform is a cytoskeletal actin, whereas α and γ isoforms colocalize
within the contractile apparatus. We found that the relative content of β-actin is similar in the
antrum and fundus. However, muscle cells from fundus contain more α-actin but less γ-actin than
antrum. Our results are in agreement with the early data of Fatigati and Murphy
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who showed

that α-actin is mainly found in arterial smooth muscle, whereas γ -actin usually predominates in
visceral smooth muscle. Szymanski et al., have also reported about two to three times more αactin in the lower esophageal sphincter than in the esophageal body, whereas γ -actin was ~43%
more in the esophageal body compared to lower esophageal sphincter100. Future functional
studies might correlate these different regional distributions of the different actin isoforms to
smooth muscle contractility.
8.1.3

Caldesmon, calponin, and tropomyosin
Besides actin, it is strongly believed now that the thin-filament-associated proteins

regulate actomyosin ATPase activity and thus modulate the rapid cross-bridge cycling formed by
actomyosin interaction; the essential event of muscle contraction. In the present study, we show
that there is a greater abundance of tropomyosin, calponin, and caldesmon in antrum compared to
fundus. It has been shown that caldesmon and calponin exert an inhibitory effect on actinactivated myosin ATPase activity and suppress contraction in a Ca2+-regulated manner56,59,60.
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Phosphorylation of caldesmon by kinases, mainly PKC and MAPK, or binding of Ca2+/CaM to
caldesmon, although with low affinity, dissociates caldesmon from F-actin and thus removes the
inhibitory effect of caldesmon on actomyosin ATPase by allowing myosin heads to interact with
the freed actin filaments and so muscle to contract123,124.
Consistent with our data, Haeberle et al., 125 have shown that caldesmon content is higher
in smooth muscles from rabbit ileum, guinea pig taenia coli, and rat uterus than in muscles
isolated from bovine aorta or porcine carotid arteries. In addition, Caldesmon level in the extreme
example of phasic muscles, chicken gizzard smooth muscle, was reported to be about twofold
higher than in vascular smooth muscle 124,125.
Regarding calponin , the recent report of faster unloaded shortening velocity in smooth
muscle of calponin knock-out mice is consistent with the suggested negative regulation of the
cross bridge cycle by calponin126. Calponin‟s inhibitory effect on actomyosin ATPase was found
to be removed via either phosphorylation by PKC or Ca2+-CaM-dependent kinase II 56 or binding
to CaM127.
Goyal and coworkers reported similar calponin content in both the phasic esophageal
body and the tonic lower esophageal sphincter smooth muscles100. The discrepancy between this
data and our calponin data could be simply a consequence of species and tissue differences, but
additional work is needed to demonstrate this possibility.
In parallel with the proposed roles for caldesmon and calponin, it was proposed that
tropomyosin might impose an inhibitory effect on myosin ATPase activity by covering and
spanning actin monomers. The removal of this inhibitory regulation, upon smooth muscle
activation, displaces tropomyosin from myosin-binding sites on actin leading to cooperative
actomyosin cross-bridge formation and muscle contraction48. Our data, which shows higher
contents of caldesmon, calponin and tropomyosin in antrum might fit with the suggested roles for
139

these thin filament-associated proteins in facilitating the accelerated relaxation and preventing the
generation of basal tone in phasic smooth muscle.
8.1.4

Smoothelin
Smoothelin is another α-actin-binding protein and is a constituent of the cytoskeleton

which is specific for smooth muscle cells in a broad range of species. It is encoded by a singlecopy gene via dual promoter system that generates two major isoforms; A (59 kDa) and B (110
kDa)
129
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. Although our knowledge about its function is still incomplete, previous embryological

and knock-out 66 studies have revealed that lack of smoothelin leads to a decreased contractile

potential of smooth muscle.

It was proposed that smoothelin A isoform is predominantly

expressed in visceral tissues while B isoform is the vascular isoform of smoothelin, although not
all vascular smooth muscle cells in arterial media express smoothelin. For example, in elastic
arteries, such as the aorta, the percentage of smoothelin-expressing smooth muscle is lower than
in muscular arteries, such as the femoral artery

64

. Consistent with those previous reports, we

found that mRNA levels of smoothelin A are greater in antrum while smoothelin B mRNA levels
are higher in fundus. More research on other different types of phasic and tonic smooth muscle
tissues is needed to flourish literature in this aspect. In addition, better understanding of
smoothelin function might be the link to its differential expression in various smooth muscle
types.
8.2

Differences in the regulation of MLCK activity
The major mechanism responsible for contraction in smooth muscle is the

phosphorylation of MLC20 by MLCK. Phosphorylation of MLC20 removes its inhibitory effect on
actomyosin ATPase and increases cross-bridge cycling that eventually leads to muscle
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contraction 23,31,130,131. It is now well-established that MLCK interacts with Ca2+/CaM with a very
high affinity, and then the formed Ca2+/CaM-MLCK complex phosphorylates MLC20.
Our results show that both mRNA and protein expression levels of MLCK are higher in
antrum compared to fundus of rabbit stomach. Our results seem to be in parallel with the results
of Szymanski et al., who found that MLCK content in esophageal body was approximately
threefold higher and phosphorylation of MLC20 was approximately fivefold faster than in lower
esophageal sphincter99. However, in spite of greater MLCK expression in antrum, AChstimulated activity of MLCK was similar in both regions. Moreover, contraction of permeabilized
muscle in response to 0.5µM Ca2+ was similar in cells from the two regions, suggesting that Ca2+dependent MLCK activity is similar in both regions. These results raise the possibility that
MLCK activity may be selectively suppressed in antrum via negative feedback mechanisms
involving other kinases such as AMPK.
It is important to note that changes in [Ca2+]i do not always lead to proportional increases
in MLCK activation. At longer time after initiation of neural stimulation, there is an apparent
desensitization of the kinase to Ca2+. This desensitization occurs when MLCK is phosphorylated
at the C terminus of its CaM-binding sequence that would decrease the affinity of the kinase for
Ca2+/CaM. This phosphorylation was shown previously to be Ca2+-dependent
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. Recent

evidence indicates that it is mediated by Ca2+-dependent activation of CaM-dependent protein
kinase kinase-β, CaMKK-β, via Gq-coupled receptors104. CaMKK-β in turn phosphorylates and
activates AMPK. Although MLC20 is not a direct downstream physiological substrate of AMPK
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but still it desensitizes smooth muscle by phosphorylating MLCK at Ser815 and thus leading to

its inhibition29. Moreover, if the concentration of AMP increases sufficiently in the contracting
muscle, AMP can also directly activate AMPK. So, both Ca2+-dependent and AMP-stimulated
feedback mechanisms would thus diminish MLCK activity.
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AMP-activated protein kinase (AMPK) is a Ser/Thr kinase heterotrimer consisting of a
catalytic α-subunit and two regulatory subunits, β and γ. It acts as an energy sensor at both
cellular and systemic levels in mammals133,134. Phosphorylation of Thr172 in the activation loop of
the catalytic α-subunit
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by upstream kinases (e.g., CaMKK-β) activates AMPK which in turn

decreases ATP consumption and stimulates ATP-producing processes
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. AMPK is

dephosphorylated and deactivated by protein phosphatase-2C (PP2C) 105.
There are multiple isoforms of AMPK that are encoded by different genes; two isoforms
of the catalytic α subunit (α1 and α2), two isoforms of the β subunit (β1 and β2), and three
isoforms of the γ subunit (γ1, γ2, γ3), that can lead to the formation of 12 different complexes
with differing properties 105.
α1 subunit is ubiquitously expressed and localized predominantly to the cytosol and hence
likely to phosphorylate cytosolic and plasma membrane substrates, whereas the α2 subunit is
expressed predominantly in skeletal muscle, liver and cardiac muscle, where it is found in both
cytosol and nuclei 105. As the primary AMPK isozyme, α1 is found in pulmonary arterial smooth
muscle 135, carotid smooth muscle 136, vascular endothelial cells and mouse aorta137.
Our results showed that both protein and mRNA expression of AMPK1 was greater in
antrum than in fundus. Functionally, ACh-stimulated AMPK activity was also greater in muscle
cells from antrum compared to fundus. AMPK activity was measured using recombinant MLCK
as substrate, implying that activation of AMPK might regulate MLCK in a feedback mechanism.
To examine such a pathway, we used STO609 compound, an inhibitor of CAMKK-β, the
upstream activator of AMPK. Our theory was that if there is a feedback inhibition of MLCK by
AMPK, then blockade of AMPK activation by STO609 should reverse this inhibition and further
augment the activity of MLCK. ACh-stimulated AMPK was blocked by STO609, which is
consistent with the fact of CAMKK-β-dependent activation of AMPK. Most importantly,
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blockade of AMPK augmented ACh-stimulated MLCK activity selectively in antrum without
changing its activity in fundus. These results imply that in antrum muscle of the stomach, MLCK
activity is rapidly terminated via a feedback mechanism involving phosphorylation and activation
of the highly expressed AMPK. Furthermore, measurements of muscle cell length via scanning
micrometry showed that contraction in response to ACh was enhanced in the presence of STO609
in anrum, but not fundus. This is again consistent with the augmentation of MLCK activity by
AMPK inhibition in antrum.
Moreover, our data clearly show that stimulation of AMPK activity is Ca2+/CaMdependent. Using either the calmodulin antagonist, calmidazolium, to inhibit the calmodulinregulated activity of CaMKK-β or BAPTA, to chelate intracellular Ca2+ abolished both ACh- and
KCl-stimulated AMPK activity in antrum without an effect in fundus (as both ACh- and KClinduced AMPK activity was minimum in fundus). These results suggest that CaMKK-β is main
upstream activator of AMPK in smooth muscles of antrum. In addition, both Ca2+ influx and Ca2+
release from intracellular stores seem to be important for CaMKK-β-mediated AMPK activation
as both KCl-induced membrane depolarization and ACh-stimulated m3 receptor activation
resulted in a significant increase in AMPK activity in antrum.
In addition, AMPK activation was found to trigger cADPR-dependent SR Ca2+ release via
RyRs in isolated pulmonary arterial smooth muscle cells by yet unknown mechanism138-140. This
effect might be of relevance in longitudinal smooth muscles where cADPR-dependent SR Ca2+
release via RyRs seems to be important especially in the intestine26.
Our MLCK activity data looks contradictory to the ones of Gong et al., in which they
found that guinea pig ileum and portal vein smooth muscles, which represent phasic muscles,
have approximately threefold higher activity of MLCK than rabbit femoral artery smooth
muscles, which represents tonic muscles141. Knowing that other non-muscle components and
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regulators might affect enzyme activity in the whole tissue homogenates, MLCK activity
measured in those tissue samples could be different than our measurements in dispersed smooth
muscle cells. In addition, differential expression and regional distribution of AMPK isoforms
could be different in these various smooth muscle organs.
Other signaling components might add to the above mentioned differences regarding the
regulation of MLCK in tonic versus phasic smooth muscles. For example, CaM-dependent kinase
II (CAMKII) protein expression was found to be higher in proximal colon, which represents
phasic smooth muscles, than in fundus 142. CAMKII might regulate smooth muscle contraction by
phosphorylating several substrates such as MLCK143 and phospholamban, a negative regulator of
sarcoplasmic reticulum Ca2+-ATPase 144. CAMKII expression profile seems to be in parallel with
the results of Goyal and his coworkers who found the total content and concentration of CaM to
be higher in the phasic esophageal body compared to the tonic lower esophageal sphincter99.
These findings might be of more relevance to other CaM-binding proteins such as caldesmon and
calponin, which we found to be higher in antrum compared to fundus.
In summary, higher expression of AMPK and greater AMPK-mediated inhibition of
MLCK in antrum is correlated with rapid contraction and relaxation cycles in antrum (figure 33).
This observation may be applicable to other phasic smooth muscles

23,145

. Future studies should

be directed towards identifying the relative and the regional importance of these regulatory
pathways in smooth muscle contraction.
8.3

Differences in the regulation of MLCP activity and muscle contraction
Phosphorylation of MLC20 by MLCK is counterbalanced by its dephosphorylation by

myosin light chain phosphatase (MLCP), an essential step in smooth muscle relaxation141. MLCP
is a holoenzyme consisting of three subunits: a catalytic subunit that is a 38 kDa-type I-protein
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phospatase delta isoform (PP1cδ) and two regulatory subunits consisting of a small 20 kDa
subunit and a 110- to 130-kDa subunit (myosin phosphatase target subunit 1, MYPT1). The
interactions of the three subunits are required to form the functional enzyme. MYPT1 subunit
contains a PP1c-binding motif occuring at the amino acids 35-38, followed by seven NH2terminal ankyrin repeats. Binding of PP1Cδ with MYPT1 alters substrate specifity and enhances
catalytic activity.
MLCP content and activity have been reported to be higher in phasic muscles of ileum,
portal vein, and gizzard than in tonic muscles of femoral artery and aorta

141,146

. Others have also

reported higher basal levels of MYPT1 in the predominantly phasic rectum smooth muscle
compared to the internal anal sphincter
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. Relatively higher content and activity of MLCP in

phasic smooth muscles may contribute to the lack of steady-state MLC20 phosphorylation and
basal muscle tone. The lack of basal tone in these muscles might be of relevance to the proposed
role and behavior of these smooth muscle types where accelerated rate of MLC20
dephosphorylation and rapid initiation of relaxation is required 23,141,145.
Phosphorylation of the MYPT1 is thought to regulate the activity of MLCP. The major
regulatory phosphorylation sites of MYPT1 are Thr696, Thr853, Ser695. Phosphorylation of Thr696
in MYPT1 by Rho kinase dissociates the enzyme from PP1cδ and inhibits the activity of the
catalytic subunit of MLCP. Phosphorylation of Thr853 by Rho kinase within the myosin-binding
domain on MYPT1 dissociates the enzyme from myosin and decreases the efficiency of the
enzyme by decreasing availabilty of the substrate. While Rho kinse can phosphorylate both Thr696
and Thr853, several other kinases have also been shown to phosphorylate the Thr696 site such as
ZIPK.
In addition to the inhibitory role of MYPT1 phophorylation at the Thr696 and Thr853 sites,
MLCP inhibition can occur via PKC- or arachidonic acid-mediated pathways. Phorbol ester- or
145

DAG-mediated activation of PKC, mainly PKC-δ and PKC-ε, 38 results in phosphorylation of the
17 kDa PKC-potentiated inhibitor protein (CPI-17), at Thr38. This phosphorylation significantly
increases the binding affinity of CPI-17 to the catalytic PP1cδ subunit of MLCP leading to
dissociation of the holoenzyme and thus inhibition of the catalytic activity

148

. Arachidonic acid

activates both Rho kinase and PKC, and sphingosylphosphorylcholine (SPC) has also been
suggested to directly activate Rho kinase149. MLCP inhibition by either PKC or Rho kinase is
thought to be the general mechanism for G-protein-dependent elevation of MLC20
phosphorylation level and thus maintaining contraction at constant [Ca2+]i; a process called Ca2+
sensitization.
On the other hand, phosphorylation at the Ser695 site of MYPT1 by PKA or PKG blocks
the ability of Rho kinase to phosphorylate the nearby Thr696 and thus increases MLCP activity.
Moreover, PKA and PKG can indirectly augment MLCP activity through phosphorylating and
thus enhancing the acivity of telokin. Telokin is an endogenous 17 kDa activator of MLCP. It is
a smooth muscle specific protein that is independently and invariably expressed in different
smooth muscles from a promoter located within an intron of MLCK gene and is thus identical to
the C-terminus of MLCK downstream from the kinase and calmodulin binding domains. The
ability of telokin to stimulate MLCP is moderately enhanced upon phosphorylation of Ser13 by
PKA or PKG.
Our results demonstrate characteristically higher levels (both protein and mRNA) of Rho
kinase II-the most common isoform of Rho kinase involved in smooth muscle contraction130,150
and CPI-17, in the smooth muscles of the fundus compared with the antrum. Our results are
consistent with the previous studies, which showed higher levels of RhoA/Rho kinase pathway
and CPI-17 in the internal anal sphincter, which represents tonic smooth muscles, compared with
the predominantly phasic rectal smooth muscle

147

146

. It is of interest that Woodsome et al.
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also

reported higher levels of CPI-17 in the tonic smooth muscle of the femoral artery than in the
phasic smooth muscle of the vas deferens. In addition, our data showed that both protein and
mRNA contents of ZIPK were similar in both stomach regions. However, stimulation of ZIPK
activity was greater in antrum compared to fundus reflecting higher expression and activation of
upstream kinase, Rho kinase.
To functionally elucidate the singular contribution of CPI-17 in the muscle contraction,
we used the PKC activator, PMA. We found that treatment of dispersed muscle cells with PMA
caused significantly, 2 to 3 folds, greater contraction in muscle cells from fundus than in muscle
cells from antrum. In contrast, the extent of PKC activation by PMA was similar in muscle cells
from both antrum and fundus. Knowing that CPI-17 is a downstream target of PKC, these results
correlate well with the higher expression of CPI-17 in the fundus compared to the antrum. Future
knockout and siRNA studies might further confirm CPI-17 role in MLCP inhibition and thus
muscle contraction in response to contractile agonist, which activate both Rho kinase/MYPT1
and PKC/CPI-17 pathways.
Moreover, our results demonstrated that ACh-induced stimulation of both Rho kinase and
ZIPK was significantly higher in muscle cells from fundus compared to antrum. Data are also
consistent with the concept that RhoA/Rho kinase components (responsible for the inhibition of
MLCP and sustained elevated levels of p-MLC20), are higher in tonic than phasic smooth
muscles. These results also clarify the relationship between the functional status and the levels of
these different signal transduction proteins in the tonic versus phasic smooth muscles in their
basal state in support of previous studies demonstrating constitutive activation of Rho kinase
pathway in tonic muscle under physiological conditions152-154.
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Low levels of RhoA/Rho kinase may unleash MLCP, causing rapid dephosphorylation of
p-MLC20, preventing the development of any basal tone, and causing rapid fade of stimulated
contraction in phasic smooth muscles such as the antrum
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. This data collectively show that

fundus is characterized with the molecular apparatus designed to provide sustained levels of
MLC20 phosphorylation responsible for the basal tone.
Interestingly, upon treating muscle cells with Y27632, a selective blocker of Rho kinase,
both Rho kinase and ZIPK activities were inhibited, suggesting that stimulation of ZIPK activity
is dependent on and downstream of Rho kinase and this might explain the higher ZIPK activity in
fundus in spite of similar contents in both antrum and fundus. Although literature is rich in
research favoring the roles of both Rho kinase and ZIPK in myosin and MYPT1 phosphorylation
and thus smooth muscle contraction, still few studies haves considered the possibility that these
two enzymes may in fact directly interact 43,156,157.
It is now believed that both Rho kinase and ZIPK cause Ca2+-independnet contraction in
smooth muscle cells. In addition, ZIPK in smooth muscle phosphorylates many of the same
substrates as Rho kinase in vitro, including MYPT1 43. Moreover, both kinases show a preference
for threonine and target similar phosphorylation site consensus sequences, i.e. 3–4 basic amino
acids +1 or +2 N-terminal to the phosphorylation site 156. Consistent with our data, Borman et al.,
found that, in smooth muscle, carbachol-induced activation of ZIPK was sensitive to Y27632
even though ZIPK is not directly inhibited by this compound in vitro 43.
However, knowing that Rho kinase is largely membrane-bound upon RhoA activation, a
question being raised is how this membrane-bound kinase can directly phosphorylate MYPT1
and myosin158,159. Morgan and co-workers have shown in their studies that stimulation of isolated
smooth muscle cells by PGF2α induces a marked change in the localization of MLCP, in which
MYPT1 is initially phosphorylated in the cytosol and then, MLCP is translocated to the
148

membrane where the subunits are dissociated. PP1c returns to the core of the cell while MYPT1
remains at the membrane location. The isolated PP1c reduces phosphatase activity towards
phosphorylated myosin and thus decreases MLC20 dephosphorylation 160.
Endo et al.,

157

demonstrated that transfection of HEK293 cells with constutively active

RhoA promoted interaction of ZIPK with MYPT1. So, it is suggested that ZIPK is a downstream
target of both RhoA and Rho kinase signaling, forming a signal transduction module to ultimately
regulate myosin phosphorylation in smooth muscle. Given the location of active Rho kinase at
the plasma membrane, mechanisms must exist to translocate ZIPK to the activated Rho kinase.
One possible mechanism might involve binding to MYPT1 where Rho kinase directly interacts
with ZIPK via translocation of MYPT1 itself from the cytoskeleton to the plasma membrane. In
another scenario, ZIPK might act as a soluble Rho kinase target to transduce the signal from the
cell membrane to the actomyosin cytoskeletal elements within the cytoplasm.
In summary, our studies identified a strong correlation between higher levels and
activities of Rho kinase/ZIPK/MYPT1 and CPI-17/PKC pathways and tonic phenotype of fundus
muscle. These studies combined with the previous studies in different sphincteric muscles in
several species suggest a pivotal role for MLCP inhibition via Rho kinase/ZIPK/MYPT1 and
CPI-17/PKC pathways in the maintenance of MLC20 phosphorylation and muscle tone (figure
33).
8.4

Differences in the regulation of MLCP activity and muscle relaxation
On the other side of MLCP regulation, telokin has been shown to activate MLCP and to

be important for cGMP-mediated calcium desensitization and thus relaxation of smooth muscle
tissues 161. Our data demonstrating higher expression of telokin in antrum compared to fundus are
in agreement with the previous studies showing higher telokin expression in urinary bladder
149

(phasic) compared to aorta (tonic)

162,163

. Higher expression of telokin and greater activation of

MLCP and relaxation in antrum compared to fundus is correlated with phasic phenotype of
antrum. This is in contrast to the higher expression of CPI-17, an endogenous inhibitor of MLCP
in fundus.
To examine the role of telokin in smooth muscle relaxation, contraction was induced by
Ca2+ in permeabilized muscle cells and relaxation in response to 8-Br-cGMP was measured. This
approach precludes the effect of 8-Br-cGMP on intracellular Ca2+ levels and reflects the effect on
MLCP probably via phosphorylation of telokin at Ser13. As the response to NO-donor was
different in antrum and fundus due to differences in the expression of PDE5 and MRP5,
relaxation in response to 8-Br-cGMP, non-hydrolyzable analog of cGMP, was measured. Our
results demonstrated that 8-Br-cGMP, caused significantly greater relaxation in muscle cells from
antrum compared to fundus. In contrast, the extent of PKG activation by 8-Br-cGMP was similar
in muscle cells from antrum and fundus. This relaxation difference between these two muscle
types is in parallel with the higher telokin expression in antrum.
These

findings

were

further

strengthened

by

the

measurements

of

MLC20

dephosphorylation (i.e., MLCP activity) in cells expressing wild type telokin and
phosphorylation-deficient telokin (telokin S13A) under conditions of where the effects of
cGMP/PKG on Ca2+ levels are precluded as described above. We found that MLC20
phosphorylation was decreased by the PKG activator 8-Br-cGMP in antrum and fundus, but with
greater inhibition in antrum. In addition, the effect of 8-Br-cGMP was attenuated in cells
expressing phosphorylation-deficient telokin (S13A), and again greater attenuation was found in
smooth muscle cells from antrum. Similar levels of MLC20 phosphorylation and contraction in
response to Ca2+ support the notion that telokin action is through the increased activity of MLCP
rather than inhibition of MLCK activity.

It is noteworthy to mention that the functional
150

contribution

of

telokin

to

relaxation

of

Ca2+-independent

contraction

and

MLC20

dephosphorylation has not been determined yet.
Taken together, our results in antrum and fundus, and those of previous studies in phasic
visceral and tonic vascular muscle, support the hypothesis that preferential expression telokin and
increase in MLCP activity contributes to higher relaxation in telokin-rich smooth muscle and
correlate with the phasic phenotype of the muscle. In contrast, lower expression of MLCP
activator, telokin, and higher expression of MLCP inhibitor, CPI-17, in tonic muscle facilitate
greater sensitivity of contractile proteins to low Ca2+ levels, a well recognized, but poorly
understood biochemical characteristic of tonic muscle. Both mechanisms of MLCP regulation
may operate in parallel in vivo to restrain MLCP activation and to maintain muscle tone (figure
33).
8.5

Differences in the regulation cGMP levels and muscle relaxation.
The main relaxant neurotransmitters of gastrointestinal smooth muscle are nitric oxide

(NO), vasoactive intestinal peptide (VIP), and its homologue pituitary adenylate cyclaseactivating polypeptide (PACAP). These neurotransmitters induce relaxation through generation
of cAMP and cGMP and activation of PKA and PKG, respectively. These kinases, in turn, target
different components of MLCK and MLCP signaling pathways that eventually induce and
augment myosin light chain dephosphorylation and consequently desensitize the process of
contraction. Although generation of both cAMP and cGMP and activation of PKA and PKG are
the physiological norm, studies in transgenic mice lacking nNOS, sGC, and PKG-Iα suggest that
cGMP/PKG plays a critical role in relaxation of smooth muscle 106-108.
Cyclic GMP levels in gastrointestinal smooth muscle are well-controlled by the balance
between the synthetic activities of soluble guanylyl cyclase, and the degradative activities of
specific PDE5, the main cGMP-specific PDE5 in smooth muscle. Soluble GC is a heterodimeric
151

enzyme made up of one α and one β subunit with α1/β1 being the most abundant and the most
widely expressed isoform of sGC. This isoform was shown to have the most basal and NOstimulated activity

164

. PDE5 is a dimer containing two allosteric cGMP-binding sites in its

regulatory N-terminal domain and a specific cGMP-binding site in its catalytic C-terminal
domain that hydrolyses cGMP. An increase in cGMP levels not only stimulates PKG, but also
augments PDE5 activity by allosteric activation via binding to its regulatory domain, and by
PKG-mediated phosphorylation of PDE5 at a conserved serine residue in the N-terminal region.
Beside degradation by phosphodiesterases, cyclic nucleotides elimination via MRPsmediated active export into the extracellular space has been found to be an important pathway in
returning cyclic nucleotide levels back to basal state. MRP5 mRNA has been detected in various
smooth muscle tissues with high transcript levels and has been shown to be competent in the
transport of cGMP. This is supported by the observation that in cerebral cells and platelets, and
after stimulation with NO, cGMP accumulation is decreased faster than it could be explained
solely by the phosphodiesterase activity

165

. Cyclic GMP secretion via MRP5 has been shown to

be unidirectional and energy dependent 72. Studies, using immunofluorescence microscopy, have
shown that MRP5 is co-expressed with PDE5 in smooth muscle cells, providing a strong
evidence that these two pathways might complement with each other in keeping cGMP levels
within a low range 166. Thus, the strength and duration of cGMP signaling depends on the activity
sGC, PDE5 and MRP5.
Our studies demonstrate higher expression of PDE5 and MRP5 in fundus compared to
antrum. As a result, intracellular cGMP levels and relaxation in response to NO-donors were
attenuated more in fundus compared to antrum (figure 34). Increased degradation and efflux of
cGMP might play an important role in rapid termination of relaxation in fundus. Relaxation of
tonic smooth muscle in response to NO is transient and the muscle regains contraction to prevent
152

continuous distending forces or reflux of materials. At the tissue level, non-muscle elements add
more complexity to the above mentioned biochemical differences in cGMP handling between
phasic and tonic muscles. For example, it was found that the density of eNOS positive neurons
was scarce in fundus part of the human stomach while their density in distal part was intensive
167

.Thus it is possible that in addition to increase in the termination of cGMP signaling, the

mechanisms responsible for generation of cGMP such as generation of NO and activation of sGC
are also constrained in fundus to facilitate tone and optimal organ function.

153

Figure 35. Differential expression and/or activation of signaling proteins involved in the
regulation of MLC20 phosphorylation in antrum and fundus of stomach correlate with the
phasic and tonic smooth muscle phenotypes, respectively. Signaling proteins shown in red
are involved in phasic phenotype and those shown in green are involved in tonic phenotype; +
and – signify stimulation and inhibition, respectively.
Antrum: Higher expression of AMPK and selective feedback inhibition of MLCK activity via
AMPK-mediated phosphorylation, and higher expression of telokin and activation of MLCP
correlate with the rapid cyclical contractile function in phasic muscle.
Fundus: Higher expression and activation of Rho kinase/ZIPK/MYPT1 and PKC/CPI-17
pathways leading to preferential inhibition of MLCP activity and sustained phosphorylation of
MLC20 correlate with the sustained contraction in tonic muscle. In addition, rapid termination of
cGMP signal and thus, muscle relaxation by degradation and efflux of cGMP via higher
expression of PDE5 and MRP5, respectively, facilitate rapid restoration of tone.
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Figure 35
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